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ABSTRACT
Breast cancer is the most diagnosed cancer type in women and its resultant
mortality is second only to lung cancer worldwide. While breast cancer is known to have
many risk factors, inflammation remains an unquantifiable risk, and it can arise from
obesity, depression, poor health, autoimmune diseases, and other conditions that cause
systemic chronic inflammation. Chronic inflammation is gaining recognition for its role
in cancer development, the potentiation of a metastatic phenotype in cancer cells, and
decreased survival in breast cancer patients. In particular, inflammatory cytokines in the
interleukin-6 (IL-6) family have been shown to promote an epithelial-mesenchymal
transition (EMT), tumor cell detachment, invasion, and metastasis. However, therapies to
inhibit IL-6 have not been successful in treating solid tumors. This is most likely due to
redundancy, as there are other inflammatory cytokines such as oncostatin M (OSM) and
interleukin-1 beta (IL-1β) that demonstrate overlapping effects in cancer progression. In
these studies, the interactions between OSM, IL-6 and IL-1were addressed. First, OSM
and IL-6 were shown to induce vascular endothelial growth factor (VEGF) in a breast
cancer subtype-specific manner. Next, OSM was assessed for its capacity to increase
circulating tumor cell numbers in mouse models of human breast cancer. Lastly, OSM,
IL-6, and IL-1β expression levels were shown to correlate with each other in breast
cancer, and high co-expression of these cytokines was shown to lead to decreased patient
survival. Furthermore, OSM was assessed for its synergistic relationship with IL-1β in
inducing IL-6 secretion from breast cancer cells. Together, these results suggest that
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inflammatory cytokines promote metastatic disease in a breast cancer subtype-dependent
manner. Importantly, these studies both provide a rationale for the development of breast
cancer therapeutic regimens that target multiple cytokines as well as help explain why
single anti-cytokine therapies have failed in clinical trials.
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CHAPTER ONE: INTRODUCTION

A Brief Overview of Cancer
Cancer describes a large group of diseases that commonly involve abnormal cell
growth and invasion and the potential for metastasis to target organs. For the most part, it
has been thought that cells become cancerous through a multi-step process that is
typically due to DNA mutations. Mutations in genes that regulate cellular growth, cellcycle regulation genes, DNA repair genes, and a multitude of other genes related to cell
transformation and migration are affected. However, by the turn of the century it became
clear that changes in DNA sequences alone could not explain the extremely
heterogeneous nature of malignancies seen by clinicians. Epigenetics, the process of
shutting down or turning on genes through histone and DNA methylation or histone
acetylation, gained a lot of attention by the end of the 1990’s and was postulated as one
of the main drivers of malignancy (1). Broadly speaking, epigenetic inhibition or
stimulation of various genes that regulate the cell cycle and growth have been well
documented. This role for epigenetics in cancer progression was a major blow to the
Knudson’s two-hit hypothesis, where mutations or damage to DNA were considered the
main drivers for the transformation of normal cells into highly aggressive metastatic
cancer cells. However, since methylation and acetylation can be targeted with various
inhibitors, therapies that target oncogenic epigenetic events are possible (2). By 2010, a
multitude of histone deacetylase (HDAC) inhibitors have been investigated for their
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potential role as therapeutics in certain malignancies (3). For example, HDAC inhibitors
have been effective against hematological malignancies, but it is still unclear as to
whether they will have positive clinical effect against solid tumors like breast cancer.
Also, recent studies on ovarian cancer indicate that there may be some positive clinical
potential for HDAC inhibitors in combination with chemotherapeutics (4).
While epigenetic aberrations are now known to be a major factor in the
development of various malignancies, the etiological origins of these alterations in the
development of cancer are not well defined. An interesting hypothesis has been
developing over the past decade that postulates that inflammation can drive epigenetic
alterations. In a study on cardiovascular disease, it was shown that inflammation
promotes DNA hypermethylation and is a strong risk factor for the development of
cardiovascular disease (5). Additional studies have shown a link between inflammation
and epigenetics in a variety of other diseases ranging from macular degeneration,
depression, and systemic sclerosis to cancer (6-9). It is also well known that localized
inflammation and systematic inflammation have a strong dietary component and that
pathological dietary habits have been shown to be a risk factor in many types of
malignancies. Interestingly, diet, inflammation, and gut flora have been recently linked to
epigenetic effects in colorectal cancer (10-12).
Inflammation is now a well-recognized driver of many aspects of malignancy
from aberrant epigenetics to DNA damage, immune evasion, and cancer stem cell
development (overview shown in Figure 1) (13, 14). Inflammation has become a
potential target in cancer therapy through the use of specific inhibitors (14). This
dissertation is a set of studies of specific inflammatory mediators and cytokines that
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promote the production of breast cancer growth factors, invasion, and metastasis, as well
as decreased survival. Specifically, we show that proinflammatory factors such as
oncostatin M (OSM) drive expression of other inflammatory cytokines, increase tumor
angiogenesis, and the number of circulating tumor cells (CTCs) in breast cancer.
Collectively, this body of research also provides a rationale for the development of antiOSM therapeutics for the treatment of metastatic breast cancer.
Breast Cancer
Global statistics indicate that breast cancer is the leading cause of cancer deaths
among women worldwide (15). However, when just taking into consideration developed
countries, breast cancer is the second leading cause of cancer deaths. This is due to the
availability of better treatments, while the less treatable lung cancer remains the deadliest
overall. In the United States, it is estimated that over 230,000 women will be diagnosed
with breast cancer and over 40,000 breast cancer-related deaths are expected to occur in
2017 (16, 17). Of all of the types of breast cancer, invasive ductal carcinoma (IDC) is the
most common and arises from the milk duct tissues in the breast (18). Breast cancer can
also arise from other tissues in the breast, such as from the glandular lobes that results in
lobular carcinoma, which make up 10-15% of all breast cancer, and from periductal
stroma that results in phyllodes tumors, which are comparatively rare (19). Inflammatory
breast cancer (IBC) is a very aggressive form of breast cancer, which accounts for less
than 3% of all breast cancer cases (20). IBC typically start out as IDC where the cells
shed and block lymphatic vessels, resulting in marked swelling and inflammation of the
breast.
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During tumor progression, IDC starts as ductal hyperplasia, progresses to atypical
hyperplasia with dysplasia, and then to ductal carcinoma in situ (DCIS), where the tumor
cells start growing abnormally in the ductal tissue, but are not yet invasive (21) (Figure
2). Finally, when the tumor cells become malignant and acquire a more aggressive
phenotype, they can penetrate through the basement membrane and into the local tumor
microenvironment (TME). At this point, the tumor is designated invasive ductal
carcinoma (IDC) and can potentially metastasize to distant organs through the lymphatic
or the circulatory systems.
Significant morbidity and mortality associated with breast cancer comes from its
metastasis to vital organs. The primary tumor itself is not typically lethal, as the breast is
not considered essential for survival. Breast cancer most commonly metastasizes to lung,
brain, liver, spine, and bone, all of which can lead to functional and structural disruptions
in the target organs (22-25). Mechanisms that promote breast cancer metastasis are still
not well understood, but it is thought that metastasis occurs by tumor cell dissemination
through the lymphatic or the blood circulatory system. In most cases, cancer cells have to
go through a phenotypic change called an epithelial-mesenchymal transition (EMT). This
process causes the cells to change from an adherent, non-motile cell into a non-adherent,
invasive, and highly mobile cell. Recent research indicates that the higher the tumor
expression level of EMT markers, the more aggressive the breast cancer cells become and
the worse the overall prognosis the patient experiences (26, 27).
Breast Cancer Metastasis
Once breast cancer cells become invasive they have the propensity to become
metastatic and migrate to distant organs. For cancer to metastasize, it must undergo a
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multi-step process called the metastatic cascade, which involves the tumor cell’s
migration from the local TME through adjacent tissue into the circulatory system. For
tumor cells to be able to move through local tissue barriers, the cells must first undergo
an EMT (28, 29). In the process of EMT, epithelial cells that are not motile and maintain
cell-cell and cell-matrix contact become mesenchymal, motile, and lose cell-to-cell
contact. These mesenchymally-transitioned cells then enter the lymphatic or blood
circulatory system in a process called intravasation (29, 30). Once the cells enter the
circulation, they are designated as circulating tumor cells (CTCs) and can extravasate, or
exit, into a target organ. CTCs that enter the circulation typically do not survive to form
metastases, and in fact only 0.1% of all CTCs survive in the circulation (31), as most
CTCs undergo apoptosis or are destroyed by the immune system. The few cells that do
survive, extravasate into a target organ, undergo the reverse of EMT called a
mesenchymal-epithelial transition (MET), and may either lay dormant (32) or develop
into a secondary metastatic tumor (33).
Metastasis does not occur to just any organ but to sites where there is some level
of microenvironment compatibility with the primary tumor cells such that the cells can
implant and grow at the secondary site. Typically for breast cancer, some of the primary
targets of metastases involve areas that are rich in capillaries and/or growth factors and
include lung, brain, bone, and liver (15, 34-36). Once the cells have metastasized, target
organ function is disrupted as the metastatic lesion grows and replaces healthy tissue.
Bone metastases are particularly insidious as they cause marked morbidity and lead to
rapid loss in quality of life, mobility loss, and intense pain that is refractory to opioid
medication (37, 38).
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A common belief is that for cancer to metastasize, the tumor has to grow to a
certain size before it is able to intravasate into the circulatory system. This is true for
many types of cancer; however, recent studies show that for breast cancer, cells can
metastasize as early as the DCIS stage when the cells are technically not supposed to be
invasive (39, 40). This may necessitate a change in the clinical paradigm for the treatment
of breast cancer, where new detection modalities need to be investigated. In addition,
there may be other risk factors that affect early dissemination of breast cancer cells. For
example, during systemic inflammation, inflammatory factors increase the propensity of
the tumor cells to become invasive (41-43).
Inflammation in Breast Cancer
Many risky behavioral factors such as smoking, high alcohol consumption,
sedentary lifestyle, depression, and high body mass index can promote chronic
inflammation (44-46). Furthermore, poor dietary choices in adolescence with refined
sugars and grains, processed meat, and low intake of vegetables have been linked to
increased serum concentrations of inflammatory proteins such as C-reactive protein and
interleukin-6 (IL-6) (46). Chronic breast inflammation arises from a multitude of factors
including obesity, chronic infection, and poorly designed breast implants (47-49).
Inflammation appears to drive breast cancer progression due to long-term insults
associated with increased reactive oxygen species, DNA damage, mutation rate, and cell
proliferation (49-54). Inflammatory cytokines such as IL-6 and others in the gp130
family are known for their role in both acute and chronic inflammation and in promoting
cancer progression (42, 55-57). In particular, increased breast cancer recurrence after
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remission has been associated with poor health in connection to systemic inflammation
(50).
Some of the downstream mediators of inflammation are cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2), which are both correlated with a poor breast cancer
prognosis (58). Aromatase activity, which increases serum estrogen levels and promotes
breast cancer cell growth, can be induced by PGE2 and other inflammatory mediators
(52, 53, 59). Interestingly, the use of non-steroidal anti-inflammatory drugs (NSAIDs) to
suppress COX-2 has been associated with decreased risk of breast cancer (60).
Inflammation caused by various inflammatory mediators and cytokines in the gp130
family increase tumor angiogenesis, survival, immune evasion, and metrics associated
with metastasis (42, 61, 62). Interestingly, no matter what the etiological origin of IBC is,
it is typically considered invariably fatal (20, 63). Together, these studies suggest that
there is an intrinsic link between inflammation and breast cancer aggressiveness and
possibly to breast cancer subtypes.
Breast Cancer Subtypes
Breast cancer is a highly heterogeneous disease where a multitude of genetic
defects can lead to tumorigenesis and metastasis. Breast cancer aggressiveness roughly
correlates with the tumor cells’ expression of estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67, a marker for
proliferation (64). Importantly, these markers are used as prognostic and therapeutic
markers in the clinic. ER and PR are intracellular steroid receptors, and the cells
expressing them tend to be dependent on estrogen and progesterone signaling for
proliferation and survival (65, 66). When breast cancer cells lose their expression of ER
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and PR, they become estrogen- and progesterone-independent (also called ER- and PR-)
and are unresponsive to therapies that ablate these hormones (67). When assessing ER
and PR expression in tissue, a binary relationship exits at the cellular level, where each
breast cancer cell either expresses or does not express ER and/or PR. On the other hand,
HER2 expression is measured on a scale from low to high above the basal level of HER2
expression by normal breast epithelial cells. High HER2 expression (HER2HIGH),
generally caused by gene amplification (68), constitutively activates various signaling
pathways such as the PI3K/AKT and mitogen-activated protein kinase (MAPK) pathways
and leads to the promotion of tumor cell proliferation, survival, and invasion (69) (65).
Furthermore, this receptor can also gain a mutation where it becomes ligand-independent
and is able to self-activate. When HER2 self-activates, the overall expression level of
HER2 may still be low but the effects of HER2 are dramatically increased.
While ER and HER2 are therapeutically targetable markers, Ki-67 is primarily
used as a marker for cell proliferation where high levels of Ki-67 staining (Ki67HIGH) in
the nucleus correlate to high levels of cellular mitosis (70). Unlike with ER, PR, and
HER2 markers, Ki-67 is strictly used as a prognostic marker as it is not a very viable
target for therapy due to the fact that nuclear proteins are very difficult to target with
small molecule inhibitors. Currently there are no known therapies or clinical trials in
progress for inhibition of Ki-67.
Using these clinically relevant breast cancer markers, ER, PR, HER2, and Ki67,
breast cancer can be subdivided into four subtypes. The breast cancer subtypes include
Luminal A, Luminal B, Triple Negative/basal-like, and Her2-type (71) (Figure 3).
Luminal A (ER/PR+ HER2LOW Ki67LOW) is the most frequent subtype in invasive
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cancers and is also the least aggressive with a good patient prognosis (72, 73). Luminal B
(ER/PR+, HER2HIGH Ki67HIGH) subtype is abundantly seen in ductal carcinoma in situ
(DCIS) and is also not very aggressive. Patients with luminal B breast cancer also have a
good prognosis. The most invasive breast cancer subtypes are triple negative breast
cancer (TNBC) (ER/PR- HER2LOWKi67HIGH) and Her2-type (ER/PR- HER2HIGH
Ki67HIGH), which both have a poor overall prognosis (73). Contributing to the poor
prognosis for patients with TNBC is the lack of targetability by therapeutic interventions,
as the current anti-ER and anti-HER2 compounds are ineffective against cells lacking
these targets.
Breast Cancer Treatment
Currently available breast cancer treatment modalities include the standard suite
of chemotherapeutics and radiation treatment along with a handful of FDA-approved
targeted therapies. ER and HER2 are the most targetable markers. When ER or HER2
levels are suppressed in the cancer cells that express them, a marked reduction in tumor
cell growth results. Currently, ER expression is targeted by drugs such as tamoxifen and
fulvestrant, while HER2 is inhibited by trastuzumab and lapatinib (74, 75). In addition,
aromatase inhibitors such as letrozole are used to reduce the overall level of estrogen in
the body to inhibit breast cancer cell growth. With these treatment modalities, both
luminal A and B breast cancer can be effectively treated. As the disease progresses and
becomes metastatic, it is more likely that the cancer will develop resistance to these
therapies as they lose their therapeutically targetable markers and progress into TNBC.
Since TNBC do not express any of these targetable markers, the existing drugs are
ineffective in suppressing breast cancer progression. In essence, patients with TNBC
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have to rely on chemotherapy and radiation alone, and if they are fortunate, in
combination with new, untested drugs in clinical trials (Figure 3) (76).
Other therapies such as gefitinib, erlotinib, and cetuximab, which all target the
epithelial growth factor receptor (EGFR), have been used for TNBC patients in clinical
trials (77). However, these therapies were not able to statistically improve patient
outcomes when compared to standard treatment alone (77). Unlike with many other types
of cancer, it is possible that TNBC is not dependent on EGFR signaling for tumor
growth, survival, and invasive capacity. The lack of treatments for distant metastases
makes metastatic TNBC the least survivable subtype with a 5-year survival rate of only
26% (17). This provides a rationale for the development of better anti-cancer therapeutics
that are effective against metastatic breast cancer.
Intracellular Pathways That Promote Breast Cancer Progression
Inflammation-driven breast cancer is associated with various signaling pathways
that are activated by inflammatory cytokines (78, 79). While there are a multitude of
intracellular signaling pathways that affect gene regulation, only a handful are well
known for promoting cancer progression. In breast cancer, pathways that are involved
include the signal transducer and activator of transcription 3 (STAT3),
phosphatidylinositol-3-kinase (PI3K), mitogen activated protein kinase (MAPK)
pathways, and nuclear factor kappa B (NFκB) (79-85). Specifically, STAT3 signaling has
been shown to increase breast cancer invasive potential by upregulating matrix
metalloproteinases such as MMP2/9 (83) and has been associated with drug resistance to
trastuzumab and doxorubicin (80, 82). The increase in MMPs by STAT3 signaling has
also been shown to increase EMT, cancer cell detachment, and migration (86).
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Furthermore, PI3K is associated with increased AKT activation and promotes breast
cancer cell survival against chemotherapeutics (81, 87). In addition, MAPK signaling
promotes similar events as STAT3 and PI3K, including cell survival (69), drug resistance
(88-90), and invasion (91), as well as promoting cell proliferation. NFκB signaling, on
the other hand, has been shown to be associated with the development of breast cancer
stem cells, which can repopulate metastases after tumor ablation by chemotherapeutics
(92). Specifically, NFκB pathway activation been shown to increase breast cancer cell
proliferation and invasion by increasing cluster of differentiation 44 (CD44) expression,
which promotes cell migration, survival, and increased stem cell-like characteristics (85).
Based on these studies it is quite evident that there is a lot of overlap in function between
the STAT3, AKT, MAPK and NFκB signaling pathways in the context of breast cancer,
suggesting that there could be synergistic effects when multiple pathways are activated
(Figure 4). Indeed, other studies show that these pathways can be activated at the same
time, which can promote a synergistic effect that drives complex breast cancer
progression (79, 81). In summary, inflammation and inflammatory pathways related to
the gp130 family of cytokines appear to be able to drive the simultaneous activation of
these signaling pathways (78, 79).
Oncostatin M and Breast Cancer
Oncostatin M (OSM), a gp130 family cytokine, acquired its name due to its
cytostatic effect on breast cancer cells and was originally thought to be a possible
therapeutic (93, 94). While this idea was popular between 1990-2000, it was later
rebuked as new research demonstrated that OSM actually inhibits the expression of tumor
suppressors (95, 96), induces EMT (97-100), recruits cancer-promoting neutrophils
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(101), and promotes metastasis (34). Furthermore, OSM signaling is associated with a
poor breast cancer patient prognosis (97). OSM is secreted by a variety of cells in the
tumor microenvironment such as tumor-associated neutrophils (TANs) and macrophages
(TAMs), as well as adipocytes (101, 102). Interestingly, since OSM can be produced by
adipose tissue, it expression levels may be increased in patients with obesity and type 2
diabetes, both of which are thought to be drivers in systemic inflammation-mediated
breast cancer progression (14, 62, 100, 103). Furthermore, OSM appears to accumulate in
the acidic breast cancer microenvironment, where it binds to ECM proteins and stays
active (98, 104, 105). Once OSM is secreted, it can act on target cells through the OSM
receptor complex (OSMR), which consists of the gp130 protein dimerized with OSMRβ
(106) (Figure 5). Once OSM binds to its receptor, it can activate a multitude of intracellular
signaling cascades.
OSM is known to stimulate the activation of three signaling pathways including
the STAT3 (107), PI3K/AKT (78), and MAPK pathways (78, 107) (Figure 5).
Additionally, OSM rarely induces a single pathway in isolation, and multiple pathways
become active at the same time (78). This leads to the multitude of OSM-induced cancerpromoting effects, which include increased vascular endothelial growth factor (VEGF)
expression, EMT, tumor cell detachment, invasive capacity, and production of other
proinflammatory factors such as S100A7 (34, 78, 97-99, 108, 109). Two other interesting
effects associated with OSM are that it may push less aggressive breast cancer cells
toward a more aggressive phenotype by suppressing ER expression and it may increase a
cancer stem cell-like phenotype (99, 110, 111). Therefore, it is thought that inflammation
stimulated by cytokines such as OSM both promotes hormone-resistance as well as drives
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cancer cells towards a TNBC phenotype (111). Together, these studies strongly suggest
that OSM is a proinflammatory factor with a multitude of effects that exacerbate breast
cancer progression and metastasis. However, there are other related cytokines such as
interleukin-1 beta (IL-1β) and the parental gp130 family member IL-6, which can have
synergistic and overlapping functions with OSM (112).
Interleukin-6, And Interleukin-1 Beta in Breast Cancer
IL-6 is a cytokine in the gp130 family and is known to bind to a receptor
composed of a dimer of IL-6Rα and a dimer of gp130 to form a tetramer receptor
complex (113). The entire signaling complex is composed of a hexameric assembly with
two IL-6 cytokines, two IL-6Rα subunits, and two gp130 subunits (113). IL-6 has been
shown to activate multiple pathways including STAT3, JNK, and MAPK (114-116),
which increase tumor cell growth, invasion, and metastasis (42, 114, 117, 118). These
effects motivated the development of therapeutic agents to inhibit IL-6 signaling
including chimeric or humanized antibodies against IL-6 and the IL-6Rα (42, 62, 119).
Anti-IL-6 therapeutic agents, such as tocilizumab that inhibits IL-6 and siltuximab that
targets IL-6Rα, have been effective against Castleman’s disease, which is characterized
by high levels of IL-6 and abnormal proliferation of B and T immune cells (120, 121).
However, despite siltuximab’s effectiveness in limiting IL-6 signaling in patients, and
despite IL-6’s known effects in cancer progression, siltuximab has been ineffective in
limiting the lethal effects of solid tumors (122, 123). This suggests that there may be
additional inflammatory cytokines related to IL-6 that contribute to cancer invasion,
metastasis, and mortality such as IL-1β, which specifically induces IL-6 in breast cancer
cells (124).
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IL-1β is a proinflammatory cytokine in the IL-1 family, and it binds to a receptor
complex composed of IL1-R1 and IL-1RAcP (125, 126). Once the receptor complex is
activated, IL-1β induces the NFB and MAPK pathways (127-129). IL-1β signaling is
able to increase tumor cell growth, invasiveness, and metastasis in vivo by the stimulated
secretion of proteases that degrade the ECM (125, 130-133). Anti-IL-1β therapeutics
have been developed (134); however, much like with the anti-IL-6 biologics, IL-1β
inhibition has not yielded positive results in patients when compared to standard
chemotherapeutics (135). These studies suggest that for breast cancer patients, inhibition
of a singular cytokine may not be enough due to the overlapping functions of these
cytokines. Common anti-inflammatory medications such as NSAIDs inhibit
cyclooxygenase 2 (COX2) expression, resulting in a decrease in prostaglandin production
and in the reduced serum levels of a wide range of inflammatory cytokines and growth
factors such as tumor necrosis factor alpha (TNF), IL-6, IL-1β, and VEGF (136-138).
Additionally, studies have shown that there may be a benefit in using NSAIDS for the
reduction of breast cancer risk (60). In conclusion, multiple cytokines may need to be
suppressed simultaneously to obtain a positive clinical effect with reduction in metastases
and increased patient survival.
Cancer Angiogenesis and Hypoxia Factors
Angiogenesis is one of the hallmarks of cancer progression, as the development of
new blood vessels is needed to oxygenate and feed the often highly metabolically active
tumor. Angiogenesis starts when tumors reach >1 mm in size, as this is the maximum
distance for efficient diffusion of oxygen and nutrients from adjacent capillaries.
Inflammation in the context of cancer has been associated with the production of the
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proangiogenic vascular endothelial growth factor (VEGF) (139-142) (Figure 6).
Furthermore, proangiogenic transcription factors such as hypoxia-inducible factor 1
(HIF1) have also been linked to inflammation, cancer stem cells, and cancer progression
(143, 144). HIF1 consists of a dimer of HIF1 and HIF1. Typically, HIF1α is regulated
by rapid degradation while under normoxic conditions or in the absence of any inducing
cytokines (145). Once HIF1α has been stabilized by hypoxia or by HIF1-inducing
cytokines, it can translocate to the nucleus after dimerizing with the constitutively
expressed HIF1β and activate gene expression of VEGF and other proangiogenic proteins
such as basic fibroblast growth factor (bFGF) (146, 147). In particular, OSM has been
shown to increase HIF1α levels through STAT3 activation that leads to an increase in the
production of VEGF (148-150). IL-6 has also been shown to increase VEGF secretion
through the induction of STAT3 phosphorylation (116). Despite the mountain of
evidence showing that VEGF promotes breast cancer progression, anti-VEGF therapies
have had limited success clinically (151). Much like with the story of the failed therapies
with anti-IL-6 and anti-IL-1β, it is likely that other proangiogenic factors play a role in
promoting tumor angiogenesis. One of the consequences of tumor angiogenesis is that the
tumor cells intravasate into the newly formed vessels and become circulating tumor cells.
Circulating Tumor Cells and Their Detection
Circulating tumor cells (CTCs) are an important element in cancer progression as
they are thought to be the primary means by which tumors promote metastasis to distant
organs (152). Specifically, high levels of CTCs in the blood of breast cancer patients have
been correlated with poor prognosis and metastatic involvement in bone, lung, and other
sites (153, 154). Current CTC detection methodologies involve the qPCR amplification
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of epithelial markers such as epithelial cell adhesion molecule (EpCAM), cytokeratin 19
(CK19), and human mammoglobin (hMAM) (155). Detection methods that are reliant on
the presence of epithelial makers such as EpCAM and CK19 have run into a few major
problems. For example, CTCs tend to lose their epithelial markers (such as EpCAM and
CK19) when they undergo EMT and intravasate into the circulation (156, 157).
Furthermore, detection methods using only epithelial markers have difficulty in
determining if the CTC is a normal circulating epithelial cell or a tumor cell (158).
Alternative methods include the use of a colony forming assay which exploits the
immortalized nature of most tumor cells (159). With the colony forming assay, blood is
collected from an individual, the red-blood cells are lysed with a hypotonic solution, and
the resultant collection of cells, which include white blood cells and possible CTCs, are
plated in tissue culture. Overtime, colonies of adherent tumor cells will grow, and each
clonal colony is counted as one CTC. However, this method also has problems including
the lengthy time involved in forming colonies and the fact that some tumor cell types fail
to form colonies below a certain concentration of cells, which can lead to false negatives.
Another alternative method for detecting CTCs includes the qPCR-based detection of
human Alu repeat transposon sequences in human cancer cells. However, this method
only works in in vivo xenograft mouse models where mouse cells have Alu repeat
sequences that are different from the human tumor cell Alu repeats (160). Effective
detection of CTCs remains problematic and controversial as the only FDA approved
method for detection of CTCs uses the CELLSEARCH® technology, which depends on
the detection of epithelial markers (153, 154, 161). This necessitates further research into
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the nature of CTCs with a search for additional useful cancer cell markers that can be
used in the detection of CTCs.
Mouse Models for Breast Cancer
The most common animal model for the study of tumorigenesis, metastasis, and
drug development is the common mouse, mus musculus. The short life span and high
metabolism of the mouse allows researchers to study the course of cancer progression in
a compressed time-scale. Typical animal experiments using mus musculus for the study
of cancer commonly last between 1-3 months, whereas in humans, studies take 1 to 5+
years. Broadly speaking, there are three types of mouse cancer models: the transgenic
tumor-forming mouse model, the human xenograft mouse model, and the syngeneic
cancer mouse model (162-164). In the transgenic animal model, the animals are
genetically modified to overexpress oncogenes such as c-Myc or have loss-of-function
mutations in tumor suppressor genes such as p53 (164). These animals spontaneously
develop tumors and are a useful model for studying neo-tumorigenesis where normal
cells transform into metastatic tumor cells in a step-wise fashion.
On the other hand, xenograft and syngeneic mouse models require an injection of
tumor cells into a target organ. Typically, cells from established breast cancer cell lines
are injected orthotopically into the 4th mammary fat pad of mice. With xenograft models,
human breast cancer cells are used in immunodeficient mice such as in athymic nude
mice, which do not have any functional T-cells (160). This prevents the immunodeficient
animals from rejecting the human breast cancer cells and allows the study of human
breast cancer in a living system. Alternatively, with a syngeneic mouse model, mouse
mammary tumor cells derived from clonal mouse populations are injected into mice with
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the same genetic background. This allows the study of tumor growth and metastatic
disease in a immunocompetent model (162). An example of such a model utilizes the 4T1
mammary tumor cell line that was derived from a spontaneous mammary tumor in a
BALB/c albino mouse. The 4T1.2 cell line was developed by selecting a clonal
population of 4T1 cells and possesses a metastatic capacity that roughly matches what is
seen in human breast cancer (165). An advantage of the syngeneic model is that the
immune system is not compromised and inflammation and immunity, so important for
metastasis, can be studied (41).
These animal models collectively give researchers powerful tools by which to
study breast cancer progression, yet they are not without their faults. Many therapies that
appear promising in in vivo animal models of breast cancer, fail miserably in the clinic.
This underlies the need for better animal models that recapitulates human breast cancer
(166). Although it is unlikely that a single animal model could ever perfectly model
human breast cancer, utilization of multiple animal models may help confirm positive
results. In addition, results from animal studies should be corroborated with available
human data to increase the likelihood of the data being clinically relevant for human
breast cancer.
Human Data Analysis
To assess the relevance of data derived from in vitro and in vivo experiments to
human breast cancer, it is often important to corroborate this data with human patient
samples and/or to data that is publicly available in various databases or repositories. An
example of such a repository is Oncomine™, which includes over 18,000 cancer gene
expression microarrays assessed from a wide variety of human cancers (167). Data can be
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downloaded from Oncomine™, and various types of gene expression and correlation
analyses can be performed. Other sources of online databases include the catalog of
somatic mutations in cancer (COSMIC), the human protein atlas, the cBioPortal cancer
genomics database, and others (168-170). Combined with a few bioinformatics tools and
some rudimentary PERL programming, these online databases can be a powerful source
of data for researchers to associate in vitro or in vivo data with actual human cancer gene
expression data.
Other sources of human patient data can be obtained from serum or tissues
obtained from breast cancer patients. Serum and tissue samples can generally be acquired
either from commercial sources and/or from hospitals/institutes that have a repository of
stored human tissue and serum samples from patients. Alternatively, a new institutional
review board protocol can be drafted to recruit patients for serum or tissue biopsy
collection for cancer research, if the already available samples are insufficient or
inappropriate for the study design. Additionally, serum samples can also be obtained
from the National Cancer Institute’s serum bank for various research studies (171). The
collected samples can then be assessed by numerous assays ranging from
immunohistochemistry, immunoblot analysis, and enzyme-linked immunosorbent assays
(ELISAs), to laser capture microdissection and qPCR. Overall, these sources of samples
and data provide researchers a diverse tool set and help move data from tissue culture and
animal models closer to clinical relevance.
Summary
The work presented in the following studies primarily investigates the gp130
family of cytokines, including OSM and IL-6, in the context of cancer angiogenesis,
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metastasis, survival, and their synergistic relationship with other proinflammatory
cytokines. In Chapter 2, co-expression of VEGF and gp130 family cytokines in relation
to patient survival is assessed. These studies found that high expression levels of these
proteins correlate with decreased breast cancer patient survival and that the level of
VEGF production in response to OSM or IL-6 is breast cancer subtype-dependent. In
Chapter 3, the role of OSM in the promotion of CTCs and lung metastases was
investigated in multiple in vivo mouse models of breast cancer. Specifically, high levels
of OSM, through injection of recombinant OSM or induction of OSM expression in
mammary tumor-bearing mice, resulted in an increase in both CTC numbers and lung
metastases, as well as in decreased survival. However, OSM had no effect on the survival
of mice when the earlier steps of the metastatic cascade were bypassed by injecting tumor
cells directly into circulation. This finding suggests that OSM is important early in the
metastatic cascade. In Chapter 4, OSM induction of IL-6 was assessed in breast cancer. It
was determined that OSM-induced IL-6 production is predicated on breast cancer cells
lacking ER. Specifically, ER+ T47D and MCF7 did not produce any IL-6 in response to
OSM, while ER+ TNBC MDA-MD-231 cells did. Furthermore, the synergistic
relationship between OSM and IL1β was evaluated, and these studies demonstrate that
OSM and IL1β activate separate signaling pathways to promote IL-6 production.
Interestingly, increased breast tumor expression of OSM, IL-6, and IL1β were all
correlated with reduced breast cancer patient survival, and all three cytokine expression
patterns were correlated with each other. Overall, these studies attempt to elucidate the
complex interplay of inflammatory cytokines in relation to breast cancer angiogenesis,
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metastasis, and survival and suggest that effective treatment of breast cancer may
necessitate the suppression of multiple cytokines.
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Figures

Figure 1.1
Chronic inflammation leads to genomic and epigenetic instability and
promotes tumor formation.
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Figure 1.1 Chronic inflammation leads to genomic and epigenetic instability and
promotes tumor formation
A, Chronic inflammation promotes the development of downstream procancerous effects seen in B. B, Inflammation increases genomic instability resulting from
DNA damage and changes the epigenetic profile of various genes. C, Genomic changes
in precancerous cells can promote the secretion of inflammatory cytokines and
chemokines in the tumor microenvironment and induce the development of reactive
oxygen species. D, The cancer cells are then able to evade the immune system, increase
cell proliferation, and invade into circulation. Once in circulation, the CTCs can then
extravasate at distant organs and form a metastatic lesion. Adapted from QIAGEN©
(172).
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Figure 1.2.

Multi-step development of invasive ductal carcinoma (IDC)

Figure 1.2. Multi-step development of invasive ductal carcinoma (IDC).
First, an epithelial cell lining the normal milk duct becomes hyperplastic and
proliferates to induce a state called ductal hyperplasia. During atypical hyperplasia, cell
organization is lost and cells lose their original shape (dysplasia). Next, it progresses into
DCIS, where the normal ductal structure is lost, and a wide variety of cell sizes and
nuclear morphologies present. Lastly, in IDC, the cells invade through the ductal
basement membrane and may potentially metastasize to distant organs. Adapted from
RnCeus.com© (173).
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Figure 1.3.

Treatment strategies for breast cancer subtypes.

Figure 1.3. Treatment strategies for breast cancer subtypes.
Luminal A and Luminal B are the most common types of breast cancer and are
the most treatable; treatments include anti-hormone and/or anti-HER2 therapies along
with traditional chemotherapy. HER2-positive, also known as HER2-type, breast cancer
responds well to anti-HER2 therapeutics. TNBC on the other hand is the least treatable
subtype of breast cancer, as it lacks the molecular targets that the current targeted
therapies inhibit. TNBC patients must rely on chemotherapy and radiation alone and/or
use novel therapies with unknown therapeutic potential. Adapted from Catalanotti V, et
al. (76).
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Figure 1.4.

Multiple signaling pathway activation in breast cancer cells.

Figure 1.4. Multiple signaling pathway activation in breast cancer cells.
Some of the most common intracellular pathways that are active in breast cancer
are the STAT3, PI3K/AKT, MAPK (MEK/ERK), and the NFB (p65/p50) pathways.
These pathways are activated in a variety of ways including the stimulation of receptor
tyrosine kinases (RTK) by ligands such as growth factors and cytokines. Once these
pathways are activated, usually through phosphorylation of target amino acids on the
pathway proteins, they can lead to downstream effects such as tumor cell proliferation
and survival, EMT, migration, invasion, and metastasis.
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Figure 1.5.

OSM induces the STAT3, PI3K, and MAPK pathways.

Figure 1.5. OSM induces the STAT3, PI3K, and MAPK pathways.
OSM is known to activate multiple signaling pathways including STAT3, AKT,
and MAPK. Once these pathways are activated by phosphorylation of target signaling
proteins, they can induce the translocation of transcription factors into the nucleus. Then
transcription of downstream target genes such as VEGF, MMPs and other proteases,
S100A7, and genes associated with osteolytic bone metastasis, all of which promote
cancer progression.
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Figure 1.6.

Tumor cells promote the development of angiogenesis.

Figure 1.6. Tumor cells promote the development of angiogenesis.
A, Once tumor cells reach a size greater than 1 mm in diameter, they may become
hypoxic and release VEGF. B, VEGF stimulates angiogenesis whereby adjacent blood
vessels proliferate, migrate, and form tubes sending new blood vessels into the tumor.
This helps with tumor cell oxygenation, nutrient uptake, and overall growth. These new
blood vessels tend to be leaky and it is thought that the porous nature of these immature
blood vessels facilitate intravasation (174). C, As the tumor grows larger, the requirement
for more blood supply is increased. Adapted from Lungevity© (175).
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CHAPTER TWO: CO-EXPRESSION OF VEGF AND IL-6 FAMILY CYTOKINES
ARE ASSOCIATED WITH DECREASED SURVIVAL IN HER2- BREAST CANCER:
SUBTYPE SPECIFIC IL-6 FAMILY CYTOKINE-MEDIATED VEGF SECRETION
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Abstract
Background: Breast cancer cell-response to inflammatory cytokines such as
interleukin-6 (IL-6) and oncostatin M (OSM) may affect the course of clinical disease in
a cancer subtype-dependent manner. Furthermore, vascular endothelial growth factor A
(VEGF) secretion induced by IL-6 and OSM may also be subtype-dependent. Here we
investigate the relationship between cytokine signaling, patient survival, and VEGF-A in
invasive ductal carcinoma (IDC).
Methods: The association between expression of cytokines, their receptors, and
VEGF was assessed with patient survival in a breast cancer subtype-specific manner
using datasets from OncomineTM. To assess specific signaling factors involved in
cytokine-induced VEGF secretion, siRNAs for hypoxia inducible factor 1 α (HIF1α) and
signal transducer and activator of transcription 3 (STAT3) were used. The levels of
VEGF secretion were then analyzed by ELISA.
Results: In IDC patients, high VEGF expression in tumors together with high
cytokine or cytokine receptor expression correlates with decreased survival. Specifically,
patient survival is significantly lower in HER2-, but not in HER2+, disease when tumor
co-expression of VEGF and OSM, OSMRβ, IL-6, or IL-6Rα is high. Furthermore,
assessment of HER2- breast cancer cells in vitro identified unique signaling differences
regulating cytokine-induced VEGF secretion. In particular, OSM signals through STAT3
and not HIF1α to induce VEGF secretion in ER- MDA-MB-231 human breast cancer
cells, while the in ER+ T47D cells, OSM signals through both STAT3 and HIF1α.
Additionally, ER- MDA-MB-231 cells only respond to OSM and not IL-6, while T47D
cells respond to both OSM and IL-6, though to a lesser extent.
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Conclusions: These results highlight that both the survival of breast cancer
patients with high co-expression of VEGF and IL-6 family cytokines, as well as IL-6
family cytokine-mediated VEGF secretion is dependent on specific breast cancer
subtype. Thus, the heterogeneity of human breast cancer in relation to IL-6 family
cytokines and VEGF may have important implications in clinical treatment options,
disease progression, and ultimately patient prognosis.
Introduction
In the United States, breast cancer is the most frequently diagnosed cancer among
women (1). With 252,710 new cases of invasive breast cancer (IBC) expected for 2017,
breast cancer remains a leading public health concern, both in the United States and
globally. One of the main concerns is the complex relationship between IBC subtypes,
clinical treatment, and long-term survival (1, 2). The current known IBC subtypes are not
able to fully capture the heterogeneous nature of breast cancer, and our current
understanding is lacking in terms of patient treatment versus survival (3). In particular,
anti-angiogenic therapies for breast cancer have had variable clinical success at best, and
at worst, show no improvement in disease free survival (4, 5). The high level of clinical
variability with anti-angiogenic therapies may be due to the highly heterogeneous nature
of breast cancer and their subsequent biomarkers (6). This underlies the need to improve
our understanding of clinical outcomes in conjunction with existing breast cancer subtype
biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2).
Current breast cancer subtype classifications depend on the evaluation of ER, PR,
and HER2 (3). Luminal A (ER+ PR+ HER2-; low Ki67) and luminal B (ER+ PR+
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HER2-; high Ki67 or HER2+) breast cancer subtypes are typically less aggressive and
display a more favorable prognosis relative to other subtypes (7-9). In contrast, cancers
classified as basal-like triple negative breast cancer (TNBC; ER- PR- HER2-) have high
frequencies of relapse and display less favorable prognoses, in large part due to the lack
of targeted therapies available to treat this subtype (3, 7). Similarly, HER2-enriched
cancers (ER- PR- HER2+) also have unfavorable prognoses (10). While superficial
differences between the subtypes are relatively well known, the specific molecular
mechanisms that drive these differences remain elusive. Specifically, increased
inflammatory markers in the serum of breast cancer patients appear to be associated with
poor prognosis (11).
Chronic inflammation promotes a maladaptive pathological state, in which
inflammatory cytokines actually promote tumorigenesis, invasion, and metastasis (12).
Cytokines of the interleukin-6 (IL-6) family, including IL-6 and oncostatin M (OSM),
have been implicated in the migration and invasiveness of human breast cancer cells (1315), while leukemia inhibitory factor (LIF) has been shown to act as a tumor/metastasis
suppressor (16-19). Moreover, both IL-6 and OSM have been shown to be capable of
directly and indirectly driving angiogenesis (20-22). Receptor complexes of the IL-6
family all consist of at least one molecule of glycoprotein 130 (gp130), as well as
subunit(s) specific to their respective receptor (23, 24). Following IL-6 or OSM ligand
binding, the gp130 receptor complexes activates the JAK/STAT, MAPK, PI3K/AKT, and
JNK pathways, thereby mediating transcription of target genes (25-30). Although IL-6
and LIF bind specifically to their individual receptors (IL-6R and LIFR, respectively),
OSM is capable of binding to both the LIFR and the OSM receptor (OSMR) (25, 31-33).
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The resultant cytokine signaling plays various roles in the development of breast cancer,
through activation of target genes involved in differentiation, survival, apoptosis, and
angiogenesis (29, 32, 34).
Angiogenesis is controlled by a balance of pro- and anti-angiogenic factors that
maintain a normal rate of blood vessel growth (35). During tumor angiogenesis, both
tumor cells and tumor-associated stromal/immune cells secrete proangiogenic factors (30,
36). The most potent proangiogenic factor, vascular endothelial growth factor A (VEGFA), promotes the survival, proliferation, and motility of endothelial cells and enhances
vascular permeability (37, 38). Other VEGF subtypes include the weakly angiogenic
VEGF-B, and the lymphangiogenic and vasculogenic VEGF-C and VEGF-D (39, 40). As
a proangiogenic factor, VEGF-A (also referred to as VEGF) regulation typically depends
on hypoxia-driven signaling through the dimeric transcription factor hypoxia-inducible
factor 1 (HIF1). As a dimer, HIF1 consists of the inducible HIF1α subunit, which when
partnered with the constitutively expressed HIF1β, binds the hypoxia response element
(HRE) (41). However, transcription factor binding sites in the VEGF promoter other than
the HRE, such as those for signal transducer and activator of transcription-3 (STAT3) and
activator protein 1 (AP1), allow transcription to be activated by numerous pathways
under both hypoxic and non-hypoxic conditions (42-45). Under non-hypoxic conditions,
IL-6 family cytokines have been shown to promote VEGF expression via activation of
transcription factors HIF1α and STAT3 (22, 30, 46, 47).
In this paper, we study the differential effects of the inflammatory interleukin-6
(IL-6)-family cytokines on breast cancer patient outcomes, as well as the induction of
vascular endothelial growth factor A (VEGF) in a breast cancer subtype-specific manner.
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Using Oncomine data, we systemically explored the co-expression of VEGF with
inflammatory cytokine components among invasive ductal carcinoma (IDC) patients
subdivided by HER2- or HER2+ status. Specifically, we found that HER2- patient
survival significantly decreases when breast tumors co-express high levels of VEGF and
high levels of OSM, OSMRβ, IL-6, or IL-6Rα. Conversely, in patients with HER2+
disease, co-expression of VEGF and these inflammatory proteins had little to no effect on
survival. Furthermore, through treatment of HER2- breast cancer cell lines with these
cytokines, we elucidate some of the specific signaling factors involved in the mediation
of VEGF secretion. Interestingly, regulation of IL-6-family cytokine-induced VEGF in
HER2- cells differed between ER+ T47D (ER+ PR+ HER2-) and ER- MDA-MB-231
(ER- PR- HER2-) cells. In T47D cells, HIF1α played a traditional role in transcriptionally
activating VEGF secretion, while in MDA-MB-231 cells, VEGF secretion was
independent of HIF1α and dependent on STAT3 signaling. These results highlight the
breast cancer subtype-specific differences in cytokine signaling that lead to VEGF
secretion, and importantly, the potential for therapeutic suppression of IL-6 family
cytokines in HER2- breast cancer.
Materials and Methods
Oncomine analysis
To explore correlations between IL-6 family cytokines, cytokine receptors, VEGF
expression, breast cancer receptor status, and patient survival, we attained the Curtis
Breast human mRNA microarray dataset from Oncomine™ (Compendia Bioscience, Ann
Arbor, MI). The constraints used to define the dataset used were “Invasive Ductal
Carcinoma” and a detailed survival status of either “Alive” or “Dead of Disease.” The
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resultant dataset was used to calculate quartiles. From these, the upper quartile (>75th
percentile) and lower quartile (<25th percentile) were selected for comparison in order to
clearly depict survival trends that may have been otherwise muddled by use of all quartile
combinations. For co-expression analysis, we calculated survival curves using patients in
the upper quartile of both VEGF and each particular IL-6 family gene (“high/high”) and
the lower quartile of both (“low/low”). Statistical analyses between survival of two
groups was calculated using a log-rank test in GraphPad Prism 5 software *p<0.05,
**p<0.01, ***p<0.001.
Tissue culture
MDA-MB-231 and T47D human breast cancer cells (ATCC) were grown in
RPMI medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin
streptomycin, and 1% sodium pyruvate and incubated at 37°C at 5% CO2. Cytokine
treatments were prepared in low serum media (1% FBS) at 25 ng/mL recombinant human
OSM (Cat#300-10T, Peprotech), IL-6 (Cat #200-06, Peprotech), and LIF (Cat# 300-05,
Peprotech) for the indicated time points. Human umbilical vein endothelial cells
(HUVECs, GlycoTech, Gaithersburg, MD) were grown in M199 medium supplemented
with 15% FBS, 50µg/mL endothelial cell growth supplement (BD Biosciences, Bedford,
MA) and 10 units/mL porcine heparin (Sigma-Aldrich, St. Louis, MO) at 37°C in
humidified 5% CO2.
For cytokine treatment, MDA-MB-231 cells were grown to 50% confluency in
RPMI 1640 with 10% FBS, 1% Penicillin/Streptomycin and 1% Sodium Pyruvate. Cells
were then starved overnight in serum-free media. Cells were treated with recombinant
human OSM (rhOSM, Peprotech Inc., Rocky Hill, NJ) in serum-free RPMI for 72 hours.
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Conditioned media (CM) was collected, cellular debris was removed following
centrifugation, and CM was stored at -80°C.
siRNA transfection
To determine the mechanism by which VEGF is induced, siRNAs pools targeting
HIF1α, STAT3, JNK1 and JNK2 were obtained from Dharmacon. In brief, 300,000
cells/well were plated in a 6-well plate and siRNAs were transfected according to the
Fast-Forward protocol as outlined by the manufacturer of Hyperfect siRNA Transfection
Reagent (Cat# 301705, Qiagen). STAT3 siRNAs were used at 25 nM and transfection
was incubated for 72 hours, serum starved, and then treated with OSM for up to 48 hours.
JNK1 and JNK2 siRNA was used at concentrations of 20 nM and transfected for 24
hours prior to OSM treatment. Knockdown was assessed via immunoblot analysis (see
below).
Immunoblot analysis
Cells were grown to 50-80% confluency before being treated with respective
cytokines and/or siHIF1α. Cells were lysed on ice with 1x RIPA buffer containing 1x
protease inhibitor cocktail (Cat# P8340, Sigma Aldrich). Lysates were run on an SDSPAGE gel, transferred onto a nitrocellulose membrane, and blocked overnight in 5% nonfat dry milk in PBS containing 0.05% Tween 20 (5% NFDM-PBST). Membranes were
incubated overnight in 0.6 µg/mL anti-HIF1α primary antibody (Dilution: 1:1000 Cat#
AF1935, R&D Systems) in 5% NFDM-PBST. Membranes were washed with PBST and
incubated with HRP secondary antibody (Cat# 705-035-003 Jackson ImmunoResearch)
in 5% NFDM-PBST for 45 minutes, developed with ECL, and imaged on X-ray film on a
Kodak 4000R Image Station.
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Signaling blots were performed as detailed above with the following antibodies:
STAT3 (Cat# 9132), p-STAT3 (Cat# 9145), JNK1 (Cat# 3708), p-JNK1 (Cat# 4668), βActin (Cat# 3700) ((1:1000, Cell Signaling Technologies).
VEGF ELISA
Analysis of VEGF secretion by MDA-MB-231 and T47D cells was assessed via
VEGF ELISA according to the manufacturer’s protocol (Cat# Dy293B, R&D Systems,
Bethesda, MD). Cells were plated at a confluency of 50,000 or 100,000 cells in a 24-well
plate and allowed to adhere overnight. The following day, cells were serum-starved in
serum free media for 6 hours and treated with cytokines for the indicated time.
Conditioned media was collected and assessed by ELISA. The absorbance was recorded
using a microplate reader (Bio-Rad) at 450 nm and background was subtracted (570 nm).
RT-PCR
Total RNA was collected from MDA-MB-231 and T47D cells using RNA STAT60 and isolated per the manufacturer’s protocol (Tel-Test; Friendswood, TX). cDNA was
synthesized according to the manufacturer’s protocol (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems, In/Life Technologies). RT-PCR primers used
were as follows: OSMRβ (510 bp): forward, 5’-TTAAAGGCCAGAGGCTATGG-3’;
and reverse, 5’-TTGACAGAAGAATTGTGGAA-3’. LIFR (420 bp): forward, 5’ATACAGATGGTGGAGTGG-3’; and reverse, 5’-TGATGGGTGGACAATAGG-3’. IL6R (618 bp): forward, 5’-GTGAGGAAGTTTCAGAACAGTCCG-3’; and reverse, 5’TGGGAGGCTTGTCGCATTTG-3’; gp130 (326 bp): forward, 5’CATGCTTTGGGTGGAATGGAC-3’; and reverse, 5’CATCAACAGGAAGTTGGTCCC-3’; and GAPDH (483 bp): forward, 5’-
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GTCAACGGATTTGGCCGTATT-3’; and reverse, 5’AAAGTTGTCATGGATGACCTT-3’.
pSTAT3 ELISA
Intracellular pSTAT3 levels were assessed by ELISA in accordance with the
manufacturer’s protocol (Cat#7146, Cell Signaling). 50,000 cells were adhered to 24 well
plates overnight in serum free media. Cells were then treated with OSM or IL6 (25
ng/mL) for the indicated times, and cell lysates were collected using 1x Cell Lysis Buffer
(Cat# 9803, Cell Signaling). The lysates were diluted 1:3 with blocking buffer (PBS0.05% Tween 20, 1% IgG-free BSA) and assessed by ELISA. Absorbance was assessed
with a microplate reader at 450 nm with background correction at 570 nm.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5 software. To
compare multiple groups, one- or two-way analysis of variance were run with Tukey’s
and Bonferroni’s post-test, respectively where appropriate on ELISA data. Survival data
was depicted as Kaplan-Meier graphs and significance assessed by the Log-rank test.
Experiments were considered statistically significant if p values were less than 0.05.
Error bars represent mean ± S.E. Experiments were performed at least three times to
determine statistical significance.
Results
Inflammatory cytokine and VEGF co-expression is correlated with decreased survival of
IDC patients
To address the importance of IL-6 family cytokines in invasive ductal carcinoma
(IDC), we correlated patient survival relative to expression levels of VEGF with OSM,
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IL-6, LIF, or their specific receptor subunits. Using the Curtis Breast dataset obtained
from OncomineTM (48), co-expression in IDC patients was compared to survival and
quantified by individual quartiles, as demonstrated for OSM and VEGF (Fig. S1A) and
OSMRβ and VEGF (Fig. S1B). Utilizing just the upper and lower quartiles, we observed
a significant correlation between high co-expression of OSM and VEGF and decreased
survival, relative to low expression of both OSM and VEGF (p=0.0190, Fig. 1A).
Similarly, decreased survival was observed in patients who had high expression levels of
OSMRβ and VEGF (p=0.0012, Fig. 1B), IL-6 and VEGF (p=0.0005, Fig. 1C), or IL6Rα and VEGF (p=0.0016, Fig. 1D) relative to those with low co-expression of each
respective gene pair. Patient survival was not statistically affected by co-expression levels
of LIF and VEGF (p=0.0578, Fig. 1E) or LIFRβ and VEGF (p=0.1020, Fig. 1F).
Together, these results highlight the importance of tumor cell co-expression of VEGF
with OSM, OSMRβ, IL-6, or IL-6Rα on the poor survival of individuals with IDC.
HER2- status dictates poor survival in IDC patients with high co-expression of OSM, IL6, OSMRβ or IL-6Rα and VEGF
As published studies have demonstrated the importance of receptor status in
breast cancer recurrence and treatment (49-51), we next analyzed HER2 status on the
survival of IDC patients according to VEGF and IL-6 family molecule co-expression.
Interestingly, high co-expression of VEGF with OSM, OSMRβ, IL-6, or IL-6Rα
correlated with the poor survival of HER2- patients but not HER2+ patients (Fig. 2).
Specifically, statistically significant decrease in survival was only observed in HER2patients with high OSM and VEGF expression (p=0.0016) and not in HER2+ patients
(p=0.5963, Fig. 2A). Decreased survival was also seen in HER2- individuals with high
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OSMRβ and VEGF co-expression (p=0.0001, Fig. 2B), high IL-6 and VEGF coexpression (p=0.0005, Fig. S2A), and high IL-6Rα and VEGF co-expression (p=0.0112;
Fig. S2B). No statistically significant change in survival was detected with the respective
HER2+ individuals (High OSMRβ/VEGF, p=0.9317, Fig.2B) (High IL-6/VEGF,
p=0.6106, Fig. s2A) (High IL-6Rα/VEGF, p=0.0671, Fig S2B). Counter intuitive to its
role as a metastasis suppressor, high expression of LIF with high expression of VEGF
also was correlated with poor survival in HER2- (p<0.0001, Fig. S2C) but not HER2+
IDC patients (p=0.2806 Fig S2C). However, no association between HER2 status and
survival was observed in IDC patients expressing high levels of LIFRβ and VEGF
(p=0.1247 and p=0.534, respectively, Fig. S2D).
Among HER2- individuals, published results suggest that ER+ patients have the
lowest rates of relapse and a considerably more favorable prognosis than individuals
expressing other receptor subtypes (49). Therefore, we examined the co-expression of
OSM and VEGF with HER2 status in individuals that did or did not express ER.
Surprisingly, in HER2- patients, ER+ status was associated with poor survival in IDC
patients with high co-expression of OSM and VEGF (p=0.0008), while ER- status had no
effect on survival (p=0.6998, Fig. S3A, B). ER status played a less significant role in
patient survival when HER2 status was associated high OSMRβ and VEGF coexpression (Fig. S3C, D). These data suggest that while ER+ HER2- patients typically
have fair prognoses (49), high tumor co-expression of OSM and VEGF greatly impacts
survival in these individuals.
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OSM mediates VEGF induction independent of HIF1α signaling in TNBC cells
Stark differences are evident when analyzing the effects of cytokine-driven
angiogenesis on patient survival, thus underling the heterogeneity of cancer subtypes. As
our data suggested, high OSM co-expression with the proangiogenic factor VEGF
resulted in poor HER2- patient survival. To uncover mechanistic differences among
breast tumor lines with differing ER status, we used two distinct HER2- cell lines, the
ER-negative MDA-MB-231 (ER- PR- HER2-) TNBC cell line and the ER-positive T47D
(ER+ PR+ HER2-) cell line, to study VEGF induction by IL-6 family cytokines.
Inflammatory cytokines have been shown to promote hypoxia-like effects thereby
inducing transcriptional activity of HIF1α, an important transcription factor for hypoxiarelated proteins such as VEGF. Treatment with OSM, IL-6, or LIF (25 ng/mL) induced
HIF1α expression by Western blot analysis in both MDA-MB-231 cells at 24 hours and
in T47D cells at 72 hours, relative to non-treated cells (Fig. 3A, B). These time points
selected as they were determined to have maximal HIF1α-induction in each cell line (data
not shown). The addition of an siRNA targeting HIF1α (siHIF1α) inhibited the induction
of HIF1α following treatment with inflammatory cytokines. Interestingly, despite the
induction of HIF1α by each of the inflammatory cytokines assessed, an increase in VEGF
secretion was observed only in cells treated with OSM. OSM treatment accounted for a
3-fold increase in VEGF secretion in MDA-MB-231 cells at 24 hours (p<0.05) and an
almost 4-fold increase in T47D cells at 72 hours (p<0.001) compared to non-treated cells,
as assessed by ELISA (Fig. 3C, D). Treatment with IL-6 or LIF did not produce a
significant change in the level of VEGF secreted. To determine if VEGF induction was
mediated through cytokine-induced HIF1α, VEGF secretion was assessed in the presence
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of cytokine and siHIF1α together. Relative VEGF secretion was not altered in
MDA-MB-231 cells treated with siHIF1α and OSM (p<0.01, Fig. 3C) relative to
untreated control, while this same treatment reduced VEGF secretion by nearly 50% in
T47D cells (p<0.001 Fig. 3D). These results demonstrate that OSM-mediated induction
of VEGF is at least partially dependent on HIF1α signaling in T47D cells, yet is
independent of HIF1α signaling in MDA-MB-231 cells. Together, this data suggests that
OSM-induced VEGF induction is likely mediated through different pathways in ER+
versus ER- cells.
To confirm a functional effect for OSM-induced VEGF production, we performed
in vitro and in vivo angiogenesis assays. Conditioned media (CM) from MDA-MB-231
cells treated with OSM induced endothelial cell tube and branch point formation, which
was suppressed by the addition of a VEGF neutralizing antibody (Fig. S4A, B). A similar
effect was observed in vivo using a Matrigel plug assay. CM from OSM-treated MDAMB-231 cells was mixed with Matrigel and injected subcutaneously in athymic female
mice resulting in a 12-fold increase in angiogenesis, as compared to CM from untreated
MDA-MB-231 cells (p<0.001, Fig. S5A, B). Together, these results suggest that OSM,
but not IL-6 or LIF, promote the secretion of a functional VEGF from breast cancer cells.
OSM strongly induces STAT3 activation in ER+ and ER- HER2- breast cancer cells
OSM is capable of binding to and activating both the OSMR and the LIFR, while
LIF binds to only the LIFR and IL-6 binds to the IL-6 receptor. Stimulation of these
receptors prompts activation of various signaling pathways including the STAT3 and
JNK pathways (23, 52-54). To confirm that these receptors were present in our cell lines,
mRNA from MDA-MB-231 and T47D cells was assessed by RT-PCR and shown to
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express OSMRβ, LIFRβ, IL-6Rα, and gp130 (Fig. 4A). Next, we sought to determine the
mechanism by which OSM induces the expression of VEGF by investigating the
activation of the transcription factors STAT3 and JNK, found downstream of OSMR.
Treatment with OSM (25 ng/mL) strongly induced phosphorylation of STAT3 (pSTAT3)
in MDA-MB-231 TNBC cells at both 15 and 30 minutes, as assessed by immunoblot. In
contrast, addition of OSM only slightly induced phosphorylation of JNK1 (pJNK1) in
these cells (Fig. 4B). Neither the addition of IL-6 nor LIF led to STAT3 or JNK1
phosphorylation in ER- MDA-MB-231 cells. In T47D cells, stimulation with both OSM
and IL-6 promoted phosphorylation of STAT3 at 15 and 30 minutes (Fig. 4C).
Phosphorylation of STAT3 was not induced in ER+ T47D cells treated with LIF. A slight
induction of JNK1 phosphorylation was observed following treatment with OSM in
T47D cells, whereas IL-6 and LIF did not produce an effect.
In both cell lines, levels of OSM-induced STAT3 phosphorylation were transient
yet sustained over time up to 72 hours, with preferential activation around 0.5 hours,
relative to treatment with IL-6 (p<0.001, Fig. 4D, E). Interestingly, treatment with IL-6
has no observed effect on pSTAT3 levels in MDA-MB-231 cells and only induced
moderate STAT3 phosphorylation in T47D cells. This highlights an important difference
between cytokine responsiveness in these cells.
Activation of STAT3 signaling is required for VEGF secretion by MDA-MB-231 TNBC
cells
As our data suggests, OSM-induced VEGF is independent of HIF1α in MDAMB-231 TNBC cells. To determine whether OSM promotes VEGF secretion via the
STAT3 pathway, we used an siRNA targeting STAT3 (siSTAT3). In MDA-MB-231
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cells, treatment with OSM and siSTAT3 suppressed VEGF secretion to near-baseline
levels (Fig. 5A). However, this complete suppression was not observed in T47D cells,
likely due to the role of HIF1α in the secretion of VEGF in this cell line (Fig. 5B). While
initial studies using a chemical inhibitor of JNK suggested that JNK signaling was in part
necessary for OSM-mediated induction of VEGF (Fig. S6A), further investigations
revealed that these effects might have resulted from the off-target suppression of STAT3
phosphorylation (Fig. S6B). However, siRNAs targeting both JNK1 and JNK2 (siJNK1
and siJNK2, respectively) had no effect on the levels of VEGF secretion in MDA-MB231 or T47D cells treated with OSM (Fig. 5C, D). Together, these results demonstrate
that OSM mediated induction of VEGF is dependent on STAT3 in MDA-MB-231 cells,
while T47D cells utilize both STAT3 and HIF1α to promote VEGF production in
response to OSM.
Discussion
The different molecular characteristics of human breast cancer have important
implications for clinical treatment options, disease progression, and ultimately patient
prognosis. Therefore, it is important to understand how molecular mechanisms are
impacted by breast cancer subtypes in order to provide patients with comprehensive
therapies targeted against their specific disease. In this study, we show the clinical
importance of tumor cell co-expression of VEGF with OSM, OSMRβ IL-6, or IL-6Rα on
the survival of individuals with HER2- invasive ductal carcinoma. Using this human
relevance to drive in vitro studies, we demonstrate that mechanistically, ER+ HER2- and
ER- HER2- breast cancer cells respond differently to IL-6 cytokines in their induction of
VEGF.
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High tumor expression of the inflammatory cytokine IL-6 has been associated
with poor survival in breast as well as cervical cancer patients (55, 56). Upregulated
OSM, IL-6, and their receptors have been associated with increased metastatic capacity
(15, 57), including increased invasion and migration (23, 27, 28, 58, 59) and the
promotion of angiogenesis (29, 30, 32, 34). Moreover, OSM has been shown to bind to
extracellular matrix proteins such as collagens, laminins, and fibronectins in an active
conformation, thereby accumulating in a breast tumor microenvironment to further
promote these effects (60). In the studies presented here, we show that high co-expression
of VEGF with OSM, IL-6, or their receptors, correlates with poor survival of IDC
patients, suggesting their potential value as negative prognostic markers and therapeutic
targets. This association was not observed among patients with high co-expression of
VEGF and LIF or LIFRβ, most likely due to the recently described role of LIF as a
metastasis suppressor (16-18).
When IDC patients were subdivided by HER2 status, our results demonstrated
that overall survival was significantly lower in HER2- patients with high OSM or
OSMRβ and VEGF co-expression than in HER2+ patients. HER2- patients also fared
much worse when their tumors had high co-expression of IL-6 or IL-6Rα and VEGF.
Considering OSM alone, high expression of OSM in HER2- individuals was by itself
associated with poor survival, while expression of OSMRβ was not (data not shown).
Taking into consideration VEGF alone, one previous study showed that high VEGF
expression was correlated with the presence of axillary nodal metastasis and lower
overall survival (OS) rates in non-luminal A breast cancer subtypes, which include
HER2- TNBC as well as luminal B and HER2 subtypes (61). Work has also been
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published describing the relationship between expression of the lymphangiogenic factor,
VEGF-C, its receptors, VEGFR2 and VEGFR3, along with the canonical VEGF receptor
VEGFR1 with disease-free (DFS) and OS (62-65). Although VEGF-C expression had a
strong impact on DFS or OS in HER2+ tumors, HER2- patients with high VEGF-C and
VEGFR1 expression had a worse prognosis overall, thus indicating a clinical relevance
between VEGF-C expression and HER2 status (62).
With respect to ER status, we observed a significant negative effect on survival in
ER+/HER2- individuals with high co-expression of VEGF and OSM or OSMRβ. This is
interesting in light of the fact that OSM has also been shown to negatively regulate
expression of the estrogen receptor itself (66). Such regulation can indicate a key element
in OSM-driven malignancy, with the possibility that ER+ tumor cells lose ER status over
time and evolve to become less susceptible to hormone therapies and more difficult to
treat (66). Furthermore, several in vitro studies have demonstrated that OSM has a greater
effect inducing epithelial-mesenchymal transition (EMT), and tumor cell detachment
effects in ER+ PR+ HER2- breast cancer cell lines such as T47D and MCF7 than on ERTNBCs like MDA-MB-231 or MDA-MB-468 (15, 30), and data not shown). Though our
analysis for this work included 1,245 IDC patients, the assessment of HER2 and ER
status yielded low population sizes suggesting that further examination may be needed. In
particular, it is difficult to draw concrete conclusions between HER2+ status in relation to
VEGF and inflammatory cytokines because of the low population sizes, even though
clear statistical significance was shown with HER2- data. Overall, these results indicate
that the inflammatory cytokines OSM and IL-6 contribute to the aggressive phenotype
seen with HER2- disease.
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Standing alone, these results suggest important differences between breast cancer
subtypes in relation to VEGF and IL6 family inflammatory cytokines. Based on our
patient data demonstrating that high levels of IL-6 family cytokines and VEGF coexpression lead to poor survival in HER2- breast cancer, we investigated cytokineinduced VEGF secretion from two HER2- breast cancer cell lines, MDA-MB-231 and
T47D. Typically, VEGF expression is regulated under both hypoxic and non-hypoxic
conditions, as the promoter region contains several response elements that allow for
VEGF regulation downstream of various signaling pathways (Fig. 6A, (42-45)). Our
studies showed that OSM, IL-6, and LIF each increased expression of HIF1α, an
important transcription factor for VEGF. However, OSM-induced VEGF was
independent of HIF1α in ER- MDA-MB-231 cells, whereas HIF1α signaling was in part
necessary for OSM-mediated VEGF induction in ER+ T47D cells. HIF1α may have other
alternate downstream effects in MDA-MB-231 cells such as the induction of
angiopoietin-like-4, which has been shown to promote an aggressive phenotype (67).
Furthermore, knockdown of STAT3 signaling ablated VEGF secretion in MDA-MB-231
cells while having less effect on VEGF secretion in T47D cells. This difference
demonstrates that TNBC MDA-MB-231 cells depend on activation of STAT3 for
induction of VEGF secretion and suggests that inhibition of cytokine stimulation may
attenuate angiogenesis in TNBC disease. To summarize, OSM-induced VEGF secretion
is dependent on the activation of STAT3 in MDA-MB-231 cells, while activation of both
STAT3 and HIF1α appear necessary for VEGF induction in T47D cells (Fig. 6B). These
results may indicate unique properties pertaining to angiogenic signaling in ER- TNBC
versus ER+ PR+ HER2- tumors.
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Though it might be expected that IL-6 should also induce VEGF secretion from
breast cancer cells, we found that in ER- MDA-MB-231 cells, IL-6 did not activate the
STAT3 pathway and therefore did not promote VEGF secretion. Previous studies have
shown that IL-6 has no effect on MDA-MB-231 E-cadherin levels (known to be signaled
through the JAK/STAT3 pathway) and on various other markers of invasion (68), which
suggests that while ER- MDA-MB-231 cells express the IL-6 receptor, STAT3 signaling
is not regulated by IL-6 in these cells. While we showed that IL-6 weakly activated the
STAT3 pathway in ER+ T47D cells, this induction was only seen through the first hour
of treatment and did not extend to 48 hours as did OSM-induced pSTAT3. Interestingly,
under innate immunological stress such as mycoplasma contamination, overall STAT3
activation was enhanced in T47D cells and pSTAT3 induction by IL-6 mirrored that of
OSM (data not shown). Mycoplasma-induced pSTAT3 has been previously seen in
airway epithelial lung cells and is thought to be part of the cause for inflammation during
mycoplasma infections (69). Overall, the activation of STAT3 signaling by OSM is
significantly greater than with IL-6 and highlights a difference in signaling magnitude
and possibly function between these two cytokines in a breast cancer subtype specific
manner.
Conclusions
Taken together, our studies demonstrate that co-expression of VEGF and IL-6
family cytokine molecules emerge as a potential negative prognostic marker, particularly
for HER2- IDC disease. Furthermore, we demonstrate that there is distinct differential
cytokine-induced signaling of STAT3 and HIF1α, which lead to varied levels of VEGF
secretion among various TNBC and ER+ PR+ HER2- breast tumor cells. Collectively,
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these results suggest that IL-6 family cytokine inhibition may have a beneficial effect on
VEGF suppression and long-term patient survival in HER2- disease.
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CHAPTER TWO: FIGURES

Figure 2.1.

Increased co-expression of OSM or OSMRβ and VEGF correlates
with decreased survival of IDC patients
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Figure 2.1. Inflammatory cytokine and VEGF co-expression are correlated with
decreased survival of invasive ductal carcinoma patient.
These Kaplan-Meier curves in Figure 1A and B are a subset of the data presented
in Supplemental Figure S1. A) Kaplan-Meier survival curves of invasive ductal breast
carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively)
present diminished survival when compared to individuals with low OSM and VEGF
expression (lower quartiles, respectively). Comparable trends appear upon examination
of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C)
IL-6 and VEGF expression, and D) IL-6Rα and VEGF expression, indicating significant
differences between upper and lower quartile survival for each group. Survival of patients
with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and
VEGF expression are not significantly different. Analysis obtained from Oncomine™
dataset entitled Curtis Breast. Log-rank test *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.2.

Co-expression of VEGF with OSM or OSMRβ appears to affect
survival in HER2- but not HER2+ subtypes
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Figure 2.2 Co-expression of VEGF with OSM or OSMRβ appears to affect survival in
HER2- but not HER2+ subtypes.
A) Kaplan-Meier survival curves of invasive ductal breast carcinoma for HER2patients and HER2+ patients by OSM and VEGF expression. In HER2- patients, high
OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated
with decreased survival when compared to patients with low OSM and low VEGF
expression (lower quartiles, respectively). However, this trend is not evident in HER2+
individuals, as no significant difference is observed between survival of patients with
OSM and VEGF expression in upper and lower quartiles, respectively. Similar trends are
observed in Kaplan-Meier survival curves for B) HER2- and HER2+ by OSMRβ and
VEGF expression. Analysis obtained from Oncomine™ dataset entitled Curtis Breast.
Log-rank test *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.3.

IL-6 family cytokine OSM induces VEGF secretion independent of
HIF1α signaling in MDA-MB-231 cells

Figure 2.3. IL-6 family cytokine OSM induces VEGF secretion independent of HIF1α
signaling in MDA-MB-231 cells.
A) Treatment with OSM, IL-6, and LIF (25 ng/mL) for 24 hours promotes
expression of HIF1α in MDA-MB-231 TNBC cells. Addition of a siRNA targeting
HIF1α (siHIF1α) ablates the effect of adding cytokines. B) T47D cells treated with IL-6
family cytokines for 72 hours express greater levels of HIF1α relative to non-treated
control. Treatment with siHIF1α reduces this effect, as assessed by immunoblot analysis.
Immunoblots are representative of at least 3 experiments. Induction of VEGF secretion is
observed following treatment with IL-6 family cytokines (25 ng/mL) for 24 hours in C)
MDA-MB-231 cells (n=5) and for 72 hours in D) T47D cells (n=3), as determined by
ELISA. Treatment with siHIF1α does not affect VEGF secretion in OSM-treated MDAMB-231 cells; however, VEGF secretion is modestly reduced in T47D cells treated with

71
OSM and siHIF1α. Data expressed as mean +/- SEM. One-way ANOVA, Tukey’s posttest, **p<0.01, ***p<0.001.

Figure 2.4.

OSM strongly induces phosphorylation of STAT3
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Figure 2.4. OSM strongly induces phosphorylation of STAT3.
A) mRNA expression by RT-PCR of OSMRβ, LIFRβ, IL-6Rα, and gp130 in
MDA-MB-231 and T47D cells. B) Treatment with OSM (25 ng/mL) for 15 minutes, 30
minutes, and 1 hour strongly induces phosphorylation of STAT3 (Tyr 705) in MDA-MB231 cells and moderately induces JNK phosphorylation (T183/Y185). Treatment with
either IL-6 or LIF (25 ng/mL) does not induce pSTAT3 or pJNK. C) Treatment with
OSM induces phosphorylation of STAT3 and JNK in T47D cells. IL-6 induces moderate
phosphorylation of STAT3 and JNK at early time points. Phosphorylation of STAT3 and
JNK was compared to control β-actin, as assessed by immunoblot analysis. Blots are
representative of three experiments. Time course experiment for STAT3 phosphorylation
upon treatment with OSM or IL-6 (25 ng/mL) for 0.25-72 hours in D) MDA-MB-231
cells, and in E) T47D cells. Treatment with IL-6 does not induce pSTAT3 expression in
MDA-MB-231 cells, while inducing moderate pSTAT3 expression in T47D cells. ELISA
was performed in quadruplicate; with each data point expressed as mean +/- SEM. Twoway ANOVA with Bonferroni post-test, *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.5.

OSM induces VEGF via STAT3 signaling

Figure 2.5. OSM induces VEGF via STAT3 signaling.
A) Treatment with OSM (25 ng/mL) and siSTAT3 suppresses VEGF secretion by
3-fold in MDA-MB-231 cells. B) Treatment with OSM and siSTAT3 moderately reduces
VEGF secretion by T47D cells. VEGF secretion was not reduced by the addition of
siRNAs targeting both JNK1 and JNK2 in either C) MDA-MB-231 or D) T47D cells.
Experiments were performed in triplicate, and data expressed as mean +/- SEM. Twoway ANOVA with Bonferroni post-test, *p<0.05, ***p<0.001.
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Figure 2.6.

Mechanistically distinct regulation of VEGF secretion in MDA-MB231 TNBC and T47D (ER+/PR+/HER2-) cells

Figure 2.6. Mechanistically distinct regulation of VEGF secretion in MDA-MB-231
TNBC and T47D (ER+/PR+/HER2-) cells.
A) The VEGF promoter can be activated by various transcription factors. B) In
MDA-MB-231 cells, OSM mediates VEGF secretion by activating the STAT3 signaling
pathway downstream of the OSMR (OSMRβ + gp130). In T47D cells, OSM regulates
VEGF secretion via both HIF1α and the STAT3 signaling pathway.
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Supplemental Materials and Methods
Endothelial Cell Tube and Branch Point Formation Assay
For the in vitro Angiogenesis Assay (Chemicon), Matrigel (50 µL) was allowed to
solidify in 96-well plates at 37°C for 90 minutes prior to the addition of HUVECs (7.5 x
103 cells). Cells were allowed to adhere for one hour in serum-free M199 medium.
Medium was then removed and the HUVECs were treated with 1) conditioned media
(CM) from untreated MDA-MB-231 cells, 2) CM from OSM-treated MDA-MB-231
cells, 3) control medium with 25 ng/mL rhOSM, or 4) control medium with 50 ng/mL
rhVEGF. Additionally, HUVECs were treated with OSM in combination with either 0.6
µg/mL anti-OSM neutralizing antibody or 0.6 µg/mL anti-VEGF neutralizing antibody
(Genentech). Tube formation was imaged every hour for an eight-hour period using 600 x
800 pixel digital images. To quantify tube formation, branch points were counted as
angle formed by an extending cellular process.
In vivo Matrigel Plug Assay
The Matrigel plug assay was performed as described previously (70) with the
following modifications. Briefly, 8-week old female athymic NCr-nu/nu nude mice were
injected subcutaneously and bilaterally in dorsal groin area with 0.3 mL of Matrigel (BD
Biosciences) containing 20 units heparin and one of the following: 1) PBS, 2) 200 ng
VEGF in PBS, 3) control MDA-MB-231 CM (concentrated 3x), 4) OSM-treated MDAMB-231 conditioned medium (concentrated 3x), 5) CM plus 0.6 g/mL anti-OSM
neutralizing antibody or 6) CM plus anti-VEGF neutralizing antibody. After 10 days, the
Matrigel plugs were removed, trimmed of mouse tissue, photographed, and weighed.
Hemoglobin was measured using the Drabkin method (Sigma-Aldrich) following
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homogenization in 0.5 mL distilled water. Concentrations of hemoglobin were calculated
from known hemoglobin concentrations based on a standard curve run in parallel.
Athymic NCR-nu/nu mice were housed in environmentally controlled rooms in the
Veteran’s Administration Medical Center animal facility in Boise, ID. All procedures
were approved by the International Animal Care and Use Committee.
JNK Inhibitor Assay
MDA-MB-231 cells were grown to 70-80% confluency on a 24-well plate with
RPMI-1640 media. Cells were treated with 100 nM JNK Inhibitor II (CAS 129-56-6, Cal
Biochem). After four hours, 25 ng/mL OSM was added for 30 minutes, after which cell
lysates were collected and examined by immunoblot analysis.
Chapter Two: Supplemental Figures

Figure 2.S1.

Mechanistically distinct regulation of VEGF secretion in MDA-MB231 TNBC and T47D (ER+/PR+/HER2-) cells
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Figure 2.S1. Increased co-expression of OSM or OSMRβ and VEGF correlates with
decreased survival of IDC patients.
Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) OSM
and VEGF (n=318) and B) OSMRβ and VEGF expression (n=389), as separated by
quartiles. As co-expression of OSM and VEGF increases, overall survival trends
decrease, with patients expressing high OSM high VEGF (upper quartiles, respectively)
exhibiting significantly worse survival (p=0.0192) than individuals expressing low OSM
low VEGF (lower quartiles, respectively). A comparable trend is observed with coexpression of OSMR and VEGF (p=0.0012). Analysis obtained from Oncomine™
dataset entitled Curtis Breast. Log-rank test *p<0.05, **p<0.01.
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Figure 2.S2. Expression of cytokines or their receptors and VEGF appears to
affect survival in HER2- but not HER2+ subtypes
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Figure 2.S2. Expression of cytokines or their receptors and VEGF appears to affect
survival in HER2- but not HER2+ subtypes.
Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) HER2and HER2+ patients by IL-6 and VEGF expression. In HER2- patients, high IL-6 and
high VEGF expression (upper quartiles, respectively) is strongly correlated with
decreased survival when compared to patients with low IL-6 and low VEGF expression
(lower quartiles, respectively). However, this trend is not evident in HER2+ individuals.
Similar trends are observed in Kaplan-Meier survival curves between HER2- and HER2+
patients by B) IL-6Rα and VEGF expression and C) LIF and VEGF expression. D) Coexpression of LIFRβ and VEGF does not significantly affect survival in either HER2- or
HER2+ patients. Analysis obtained from Oncomine™ dataset entitled Curtis Breast. Logrank test *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.S3. Co-expression of OSM or OSMRβ and VEGF differentially affects
survival based on estrogen receptor status
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Figure 2.S3. Co-expression of OSM or OSMRβ and VEGF differentially affects survival
based on estrogen receptor status.
Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) HER2/ER- and HER2+/ER- patients and B) HER2-/ER+ and HER2+/ER+ patients by OSM
and VEGF expression. In patients with either HER2+/- and ER- expression, OSM/VEGF
expression levels do not significantly affect survival. However, in HER2-/ER+ patients,
high OSM and high VEGF expression (upper quartiles, respectively) is strongly
correlated with decreased survival when compared to patients with similar receptor status
expressing low OSM and low VEGF expression (lower quartiles, respectively). Similar
trends respective of receptor status are observed in Kaplan-Meier survival curves for C)
HER2-/ER- and HER2+/ER- patients and D) HER2-/ER+ and HER2+/ER+ patients by
OSMRβ and VEGF expression. While no correlation between OSM/VEGF expression
and survival is observed in HER2+/ER+ patients, the low number of samples in these
populations distorts our ability to make a robust assessment of this patient subset.
Analysis obtained from Oncomine™ dataset entitled Curtis Breast. Log-rank test
*p<0.05, **p<0.01.
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Figure 2.S4. OSM induces endothelial cell tube formation and branch points in
vitro
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Figure 2.S4. OSM induces endothelial cell tube formation and branch points in vitro.
Tube formation of human umbilical vein endothelial cells (HUVEC) cells treated
for 4 hours with conditioned media from A) MDA-MB-231 treated with OSM (25
ng/mL) with or without anti-VEGF neutralizing antibody (0.6 µg/mL); light microscopy,
200X. Increased tube formation is observed in HUVECs incubated with conditioned
media (CM) of OSM-treated breast cancer cells, as compared to HUVECs incubated with
control CM. B) Quantification of branch points was obtained by counting the number of
tube-like protrusions originating from each cell node. A two-fold increase in branch
points is observed in HUVECs treated with CM of OSM-treated MDA-MB-231 cells
compared to non-treated control CM. The addition of anti-VEGF neutralizing antibody
reduces branch point numbers to control levels, while anti-OSM neutralizing antibody
shows a partial effect. Addition of recombinant VEGF or OSM to untreated cell CM are
included as controls. Data expressed as mean +/- SEM. One-way ANOVA with Tukey’s
post-test, ***p<0.001, n=5.
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Figure 2.S5. OSM-treatment of human breast cancer cells stimulates angiogenesis
in vivo
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Figure 2.S5. OSM-treatment of human breast cancer cells stimulates angiogenesis in vivo.
Six- to eight-week old female athymic nude mice were injected with 0.3 mL of
Matrigel containing heparin (20 units) and 100 L of one of the following: 1) PBS; 2)
untreated MDA-MB-231 cell conditioned medium, concentrated 3-fold (3X); 3) OSMtreated (25 ng/mL) MDA-MB-231 cell conditioned medium (3X); 4) OSM-treated
medium (3X) + anti-OSM neutralizing antibody (0.6 g/mL); 5) OSM-treated medium
(3X) + anti-VEGF neutralizing antibody (0.6 g/mL); or 6) untreated control cell
medium + rhVEGF (50 ng/mL). After 10 days the mice were euthanized and the Matrigel
plugs were removed. A) Representative plugs containing various treatments were
photographed. B) Quantification of new infiltrating vessel formation was determined by
the measurement of the amount of hemoglobin in each Matrigel plug using the Drabkin’s
assay. Hemoglobin levels increases 12-fold for OSM-treated conditioned medium over
untreated conditioned medium. Data was analyzed from at least 6 replicates per
condition. Data expressed as mean +/- SEM. One-way ANOVA with Tukey’s post-test,
***p<0.001.
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Figure 2.S6. JNK Inhibitor 2 suppresses VEGF secretion and phosphorylation of
STAT3
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Figure 2.S6. JNK Inhibitor 2 suppresses VEGF secretion and phosphorylation of STAT3.
A) MDA-MB-231 cells were treated with JNK Inhibitor 2 or control DMSO for 2
hours prior to treatment with OSM (25 ng/mL). VEGF levels were assessed following
treatment with OSM for 48 hours by ELISA. JNK Inhibitor 2 suppresses overall VEGF
levels by roughly 50%. JNK ELISA was performed in triplicate. B) Phosphorylation of
STAT3 is suppressed in cell lysates collected from cells treated with JNK Inhibitor 2 and
OSM, as assessed by immunoblot analysis, indicating non-specific effects of the JNK
Inhibitor. For the VEGF ELISA, the data was expressed as mean +/- SEM, and assessed
by two-way ANOVA with Bonferroni post-test was run; **p<0.01, ***p<0.001.
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Abstract

Systemic and chronic inflammatory conditions reduce patient survival and have
been associated with increased breast cancer aggressiveness. This paper characterizes the
role of an inflammatory cytokine oncostatin M (OSM) and its role in the preintravasation aspects of breast cancer metastasis. First, we established the expression
pattern of OSM in human breast cancer tissue using tissue microarray analysis and found
that OSM was expressed at highest levels in ductal carcinoma in situ (DCIS) when
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compared to invasive ductal carcinoma (IDC), lymph node metastasis, or adjacent normal
tissue. This finding suggests that OSM may be operant during earlier steps of breast
cancer metastasis. To investigate this further, both xenograft and syngeneic orthotopic
mouse models of breast cancer were utilized. In mice bearing MDA-MB-231-Luc2
tumors, injection of rhOSM not only increased metastases to the lung and decreased
survival, but also increased circulating tumor cell (CTC) numbers. This is the first time
that a gp130 family inflammatory cytokine has been shown to directly affect the amount
of tumor cells found in circulation. These findings are corroborated using a 4T1.2
syngeneic mouse model of breast cancer. Mice bearing 4T1.2-shOSM tumors with KD
tumor expression of OSM had reduced CTCs, lowered lung metastatic burden, and
increased survival compared to mice bearing control tumors. CTC numbers were further
reduced in OSM knockout mice bearing the same tumors, demonstrating the importance
of both paracrine- and autocrine-produced OSM in this process. On the other hand, after
bypassing initial steps of metastases by injecting the 4T1.2 cancer cells directly into the
circulatory system, OSM did not affect survival. During in vitro studies, OSM induced
both 4T1.2 tumor cell detachment and migration. Collectively, we suggest that OSM
affects the early steps of metastatic breast cancer progression and that suppression of
OSM may help prevent breast cancer metastasis.
Introduction
The inflammatory gp130 family of cytokines has been shown to modulate
immune function (1) with important implications in tumor immunology (2).
Inflammation and inflammatory cytokines have been associated with increased breast
cancer metastasis and poor survival rates (3-6). Interleukin-6 (IL-6), as a well-known
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inflammatory cytokine in the gp130 family, promotes breast cancer metastasis but
therapies targeted against it have failed in clinical trials (7, 8). Other cytokines in the
gp130 family such as oncostatin M (OSM) also modulate inflammation, and OSM has
been associated with a wide variety of disease states such as in inflammatory bowel
disease, arthritis, gingivitis, and lupus nephritis (9-12). In the context of cancer, OSM has
been shown to induce in vitro metrics associated with cancer invasiveness and promote
breast cancer metastasis to bone (13-17). In the breast tumor microenvironment (TME),
OSM is produced by breast tumor cells (13), as well as stromal cells such as tumorassociated macrophages and neutrophils and adipose tissues (18-20). After OSM is
secreted, it binds to and accumulates in the extracellular matrix (ECM) in an active form,
which may lead to chronic local inflammation and increased tumor metastasis (21).
Specifically, it has been shown that human breast tumor cells signal neutrophils to secrete
OSM, which subsequently induces tumor cell vascular endothelial growth factor (VEGF)
production, cell detachment, and invasive capacity (18). Collectively, these studies
suggest that OSM functions in breast cancer progression both in an autocrine and
paracrine fashion.
OSM signaling utilizes two receptors. OSM binds with high affinity to the OSM
receptor (OSMR) (gp130 subunit + OSMRβ) and with lower affinity to the leukemia
inhibitory factor receptor (LIFR) (gp130 + LIFR (22). While OSM binding to the
OSMR has been shown to promote cancer cell malignancy and reduce long-term survival
in breast cancer patients (23), activation of the LIFR appears to suppress tumor growth
and metastasis (24). OSMR signaling initiates the JAK/STAT, MAPK, and PI3K/AKT
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pathways (25-27), as well as the stress-activated mitogen-activated protein kinases p38
and JNK pathways (28).
As a pleiotropic cytokine, OSM seems to play an important role in promoting
breast cancer metastatic potential in vitro while inhibiting breast tumor cell proliferation
(10, 29, 30). OSM has been shown to function on breast and various other cancer cells in
culture to: i) promote an epithelial-mesenchymal transition (EMT) and a stem cell-like
phenotype (27, 31, 32), ii) upregulate expression of proteases such as matrix
metalloproteinases (MMPs) (10, 15), iii) promote tumor cell detachment and subsequent
invasion (15, 16, 33), iv) induce the expression of VEGF, hypoxia inducible factor 1
alpha (HIF1α), and other proangiogenic factors (33-36), and v) suppress estrogen
receptor alpha (ERα) expression, (23). Despite increasing evidence in vitro, limited
studies have addressed the role of OSM in breast cancer metastasis in vivo.
Our lab’s previous studies were the first to show the importance of OSM in breast
cancer metastasis to bone. Specifically, reduced tumor cell-produced OSM expression led
to a decrease in osteolytic bone metastasis in an orthotopic 4T1.2 mouse model (17).
Along with earlier studies demonstrating OSM’s function in normal bone homeostasis
(37, 38), this work suggests an important role for OSM during post-intravasation breast
cancer metastasis to bone and subsequent bone destruction. While in vitro studies suggest
that OSM promotes the early steps of the metastatic cascade, no extant work
differentiates between OSM’s impact on pre- versus post-intravasation aspects of the
breast cancer metastatic cascade.
This paper demonstrates that OSM initiates pre-intravasation steps of the
metastasis cascade, increasing CTC numbers and lung metastases and decreasing
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survival. Conversely, we also show that OSM had no effect on mouse survival in the
post-intravasation model that bypassed the early steps of metastasis by injecting tumor
cells directly into circulation. Therefore, our work suggests that therapeutic suppression
of OSM in the tumor microenvironment might not only be an effective treatment strategy
for bone metastasis; it could also be used as a preventative therapeutic to mitigate overall
breast cancer metastasis.
Materials and Methods
Tissue microarrays
Breast tissue from 72 patients was obtained from paraffin block archives at the
Department of Pathology, Mercy Medical Center, Nampa Idaho. Three tissue microarrays
(TMA) of 1 mm thickness were assessed. The TMAs were stained for OSM using the
Histostain Kit (Cat #95-9843; Invitrogen, Carlsbad, CA) per manufacturer’s instructions.
The TMAs were deparaffinized and stained overnight with 1:400 dilution of rabbit antihuman OSM primary antibody (Cat #sc-129; Santa Cruz Biotechnology, Santa Cruz, CA)
and 1 hour with 1:1000 goat-anti rabbit IgG-AP 2o antibody. TMAs stained with
secondary antibody alone served as the negative control, and spleen and salivary gland
served as positive controls for OSM staining.
The TMAs were analyzed in multiple sets of random orders for OSM expression
intensity by a pathologist graded as follows: 0=No staining; 1=Light staining; 2=Medium
staining; 3=Dark staining. Gradings for each patient were averaged for each cell tissue
type (ductal epithelial, vessel, stroma). Additional methods are detailed in the
Supplemental Materials and Methods.
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Cell lines and culture conditions
MDA-MB-231 D3H2LN luc2 cells (Caliper Life Sciences); and MDA-MB-231
(ATCC) human breast cancer cells were cultured in RMPI media supplemented with 10%
FBS and 100 units/mL of penicillin and streptomycin. Cells were maintained at 37 oC,
5% carbon dioxide, and 95% humidity. 4T1.2 mouse mammary cancer cells were
cultured in alpha-MEM media supplemented with 10% fetal bovine serum (FBS), 1 mM
sodium pyruvate, and 100 units/mL each of penicillin and streptomycin, and passaged for
no more than 6 months. All media and supplements were obtained from Hyclone (Logan,
UT).
Plasmid construct design and cell transfections
To transduce MDA-MB-231-Luc2 D3H2LN cells with a tetracycline (TET)inducible vector, the full-length OSM cDNA was cloned into the pLenti 6.3/TO/V5DEST vector. Lentiviral transduction of the pLenti 6.3/TO/V5-DEST+hOSM vector and
pLenti3.3/TR vector was performed using the ViraPower™ II Lentiviral Gateway®
Expression System (Life technologies, K367-20) in accordance with manufacturer’s
instructions. Stably transduced cell lines were tested for TET induction of hOSM
expression by ELISA and Western Blot.
To create OSM knockdown 4T1.2 cells, OSM shRNA and a LacZ shRNA
sequences were cloned into the pSilencer 4.1 plasmid and stably transfected into 4T1.2
cells as previously described (17).
ELISA
OSM produced by tetracycline (TET)-inducible MDA-MB-231 (MDATO/OSM)
cells were tested for in vitro activity. MDATO/OSM cells were treated with 0.1 mg/mL
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tetracycline for 48 hours to generate conditioned media (CM) containing OSM. The CM
was then applied to parental MDA-MB-231, MDA-MB-231-Luc2, or T47D cells for 30
minutes. Respective cell lysates were then collected from treated cells using the
PathScan® Sandwich ELISA Lysis Buffer (Cell Signaling, Cat# 7018). The lysates were
then run on a PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA in accordance with
the manufacturer’s instructions (Cell Signaling, Cat# 7146).
To assess OSM concentration in animal serum, whole blood was collected from
(MDATO/OSM) tumor xenograft animals at the experimental endpoint and allowed to
coagulate for 30 minutes. The coagulated blood was centrifuged at 2,500 RPM for 10
minutes and the upper layer collected as serum. The serum was then diluted 1:3 in PBS
and used in the hOSM ELISA (R&D systems, DY295), which was performed in
accordance with manufacturer’s instructions.
Western blot analysis
OSM was induced in MDATO/OSM cells for 48 hours with 0.1 mg/mLtetracycline
in 10% FBS RPMI 1640 media. The CM was collected, run on a gel, and blotted onto
0.22 µM PVDF membranes (Millipore). Membranes were blocked using 5% nonfat dry
milk (NFDM) diluted in PBS at pH 7.4 with 0.05% Tween-20. Anti-human OSM
antibody (Santa Cruz Biotechnology, Cat# sc-129) was used at 1:1000 dilution in 5%
NFDM-PBS-T, and a secondary anti-rabbit-HRP (Jackson Immunologicals, Cat# 711035-152) was used at 1:5000 dilution in 5% NFDM- PBS-T.
Animals and tumor cell injections
Six-week-old female athymic nude mice were used for the xenograft experiments,
and six-week-old female Balb/c mice were used for the syngeneic studies. All mice were
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obtained from the National Cancer Institute’s Animal Production Facility (Frederick,
MD). OSM knockout Balb/c mice were backcrossed from OSM knockout C57BL/6 mice
that were a kind gift from Dr. Peter Donovan, indirectly, through Dr. James Ihle (St.
Jude’s Children’s Hospital, Memphis, TN). Animals were backcrossed for at least 10
generations and genotyping was done at each generation to ensure the presence of the
knockout allele. Non-surgical orthotopic injections were performed as described
previously with 2.0 x 106 cells diluted in 50 µL of PBS containing 10% medium for the
xenograft model, and 1 x 105 cells for the syngeneic models. (17). For all animals,
starting at 2 weeks post-injection, tumor length and width were measured by mechanical
calipers 3 times a week and tumor volume was extrapolated using the following equation
(tumor volume = (length x width^2) /2). “Survival endpoint” was defined by the IACUC
as tumor size greater than 20 mm in diameter, 10% or more weight loss, and/or
appearance of cachexia. At the experimental endpoint animals were sacrificed, their
organs harvested and examined for any abnormalities. Further analysis specific to each
model is described below.
For peri-tumoral OSM injections, either 50 µL PBS or 1 µg recombinant fulllength human OSM (Peprotech) diluted in 50 µL PBS was injected into the area
surrounding the tumor three times per week until the end point of the experiment. When
the tumors became palpable, mice were randomized into groups and began receiving pertumoral injections.
For the TET-OSM-inducible MDA-MB-231 (MDATO/OSM) experiments, the
OSM-induced group was given 2% sucrose water containing 0.1 mg/mL tetracycline,
while the control mice were given just 2% sucrose water until the endpoint of the
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experiment. To assess blood platelet numbers, blood was collected at endpoint into
EDTA-coated blood sample tubes (Cat# BD Biosciences, Franklin Lakes, NJ) and
complete blood count (CBC) analysis was performed by WestVet Veterinary Clinic
(5024 W Chinden Blvd, Garden City, ID).
In vivo bioluminescence imaging and tumor progression
Bioluminescence imaging (BLI) of live animals was initiated at 13 days after cell
injection and performed weekly. Three to five mice were imaged at one time. Ex vivo
organs were also imaged using BLI. Both procedures follow our previously described
protocols (39).
Detection of circulating tumor cells (Alu qPCR)
The detection of human circulating tumor cells in mouse blood was performed as
described previously (40). A human DNA standard curve was prepared by adding a
specified number of human MDA-MB-231 cells into mouse blood, and then the DNA
was isolated for use in the qPCR reactions. Genomic DNA was isolated from 100 uL of
whole blood collected from mice at the end of the experiment. DNA was isolated using
the DNeasy Blood & Tissue kit (Qiagen Cat# 69581) using the manufacturer’s standard
instructions. DNA concentrations were normalized between each sample and 4.5 ng of
DNA was added to each 25 µL qPCR reaction. The qPCR reaction mixture was obtained
from the SYBR GoTaq qPCR Master Mix (Promega, Cat# TM318, Madison WI), and
reaction mixtures were prepared in accordance with manufacturer recommendations. To
each reaction, 0.125 µL of 100 µM human Alu and GAPDH primers were added. The
primer sequences used for Alu were (s:CACCTGTAATCCCAGCACTTT
a:CCCAGGCTRGGAGTCGCAGT), and for GAPDH the sequence used was (s:
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ATGACATCAAGAAGGTGGTG; a: CATACCAGGAAATGAGCTTG). Reaction
conditions were: 50 oC for 2 minutes, 95 oC for 3 minutes and 40 cycles of: (95 oC 00:15,
60 oC 00:30, 72 oC 00:30) and fluorescence measurements were taken during the
annealing temperature stage (60 oC). Ct values were determined and the final results were
normalized to GAPDH signal levels.
Quantitative PCR (qPCR)
For quantitative analysis of lung metastases, lungs dissected from mice bearing
mammary tumors were snap-frozen in liquid nitrogen and pulverized into a fine powder.
DNA was extracted using an STE buffer (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM
EDTA) containing 20 μg/mL of proteinase K and purified by two phenol/chloroform (1:1
v/v) extractions followed by ethanol precipitation. The ratio of cancer cells to normal
cells was quantified by measuring the neomycin resistance gene (neor) DNA levels versus
the vimentin DNA loading control, as described previously (41). Taqman PCR was
performed on an Applied Biosystems 7500 real-time thermocycler. Probe and primer
sequences are listed in Supplemental Table 1. The cycling conditions were run as
follows: 50 oC for 5 minutes, 95 oC for 2 minutes, then 40 cycles of 95 oC for 1 minutes
and 60 oC for 45 seconds. Fluorescence was measured every cycle after the annealing step
and threshold cycle number (Ct) values were calculated. The data was analyzed using the
comparative DCt method (42).
In-vivo magnetic resonance imaging
Respiratory-gated, spin-echo magnetic resonance (MR) images of mice were
collected in an Oxford Instruments (Oxford, UK) 4.7 tesla, 40-cm bore magnet. The
magnet was equipped with Agilent/Magnex (Yarnton, UK) actively shielded, (21-cm
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inner diameter, ~30 G/cm, ~200 ms rise time) gradient coils and International Electric
Company (Helsinki, Finland) gradient power amplifiers and interfaced with an Agilent/
Varian NMR Systems (Santa Clara, CA) DirectDriveTM console. Data was collected
using a Stark Contrast (Erlangen, Germany) 2.5 cm birdcage RF coil. Prior to the
imaging experiments, mice were anesthetized with isoflurane and were maintained on
isoflurane/O2 (1-1.5% v/v) throughout data collection. Animal core body temperature was
maintained at 37 ±1 oC by circulation of warm air through the bore of the magnet. During
the imaging experiments, the respiration rates for all mice were regular and ~2 sec-1.
Synchronization of MR data collection with animal respiration was achieved with a
home-built respiratory-gating unit (43) and all images were collected during postexpiratory periods. Imaging parameters are TR=3 s, TE=20 ms, FOV=2.5 cm2, Data
matrix = 128 x 128; slice thickness = 0.5 mm; number of averages (NEX) = 4. Lung
tumors were manually segmented with ImageJ (rsbweb.nih.gov/ij), and the number and
volume of all metastatic tumors were measured and recorded, on an animal-by-animal
basis, as described previously (43).
Detection of circulating tumor cells (clonogenic assay)
Colony forming assays were performed to detect circulating tumor cells in mouse
blood. At the end point of the animal experiment, whole blood was collected via
intracardiac puncture into EDTA-coated tubes. Red blood cells (RBCs) were lysed with
RBC lysis solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA diluted in ddH2O)
for 4 minutes. The remaining cell mixture, containing white blood cells and circulating
tumor cells, was spun down and washed 2X with PBS. The cell pellet was then
resuspended in MEM-alpha with 10% FBS, and plated and incubated at 37 oC for 7-10

106
days until colonies formed. The colonies were then fixed with 10% formalin in PBS for
15 minutes, stained with coomassie blue and counted.
Epithelial-mesenchymal transition assay
4T1.2 mouse mammary cancer cells were plated on a 6-well plate to a confluence
of 30% in alpha-MEM with 10% FBS and 1% penicillin - streptomycin. Following a
period of 24 hours to allow for cells to adhere, 25 ng/mL recombinant mouse OSM
(rmOSM) was added to appropriate wells. Photomicrographs were taken at a power of
100x at times of 24 hours and 48 hours to observe phenotypic EMT changes over the 2day period.
Cell migration assay
4T1.2 cells were plated on 6-well plates to a confluency of 80% in alpha-MEM
with 10% FBS. After the cells attached overnight, a straight scratch on the cell monolayer
was made with a sterile 1000 L polypropylene pipette tip, and loose cells and debris
were washed away with three sterile PBS washes. The cells were then treated with or
without 25 ng/mL rmOSM, and imaged every day for 3 days on the same part of the
scratch using negative phase contrast microscopy. The images were then imported into
ImageJ (NIH), and raw unmigrated area was measured by calculating the number of
pixels in the area with no migration. Relative migration intensity was calculated using
this formula: Migration intensity = (Day 0 unmigrated area / Day n unmigrated area) -1
Cell detachment assay
4T1.2 mouse mammary cancer cells were plated on 24-well tissue culture dishes
to a confluency of 80% in alpha-MEM with 10% FBS. The cells were allowed to attach
overnight, and rmOSM (25 ng/mL, R&D systems) suspended in alpha-MEM, 10% FBS
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media was added to the cells. For up to 8 days, cells that were detached were collected
and counted by hemocytometer and viable cells were detected by lack of trypan blue
(CAT# SV30084.01, Hyclone) staining.
Statistical analysis
Statistical comparisons between multiple groups were assessed by one or two-way
ANOVA using Tukey’s post-test analysis. Comparisons between two groups were
analyzed by student’s t-test (two-tailed, unpaired). The statistical analyses were
performed by using Prism GraphPad 5.0b software (GraphPad Software Inc., San Diego,
CA). Survival data was analyzed using the Log-rank (Mantel-Cox) test. Asterisks denote
*p<0.05, **p<0.01, or ***p<0.001.
Results
High OSM expression in breast ductal carcinoma in situ (DCIS) and IDC suggests
autocrine signaling
To assess breast epithelial cell expression and location of OSM in human breast
tumors, tissue microarrays (TMAs) containing samples from 72 patients were analyzed
by immunohistochemistry. Interestingly, staining intensity was highest in the DCIS group
compared to normal tissue, while 2o antibody alone showed little staining (Fig 1A). The
mean staining intensity for normal adjacent tissue (1.33) was significantly lower than that
of DCIS (2.00) and IDC (1.66) tissues, while metastatic tissue (1.24) was statistically
similar to normal tissue (Fig. 1B and Table 1). These results suggest that OSM protein
levels are higher in the earlier stages of breast cancer and that tumor cell-produced OSM
may be important in autocrine signaling for the promotion of tumor progression.
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OSM generated from TET-inducible MDA-MB-231 (MDATO/OSM) cells increases
metastases to the lung and decreases survival
In order assess the effect of cancer cell-produced OSM in a tumor
microenvironment, we developed a stably-transduced triple negative breast cancer
(TNBC) MDA-MB-231-Luc2 D3H2LN cell line that secretes OSM in response to
tetracycline treatment (+TET; MDATO/OSM). To compare the OSM produced by the
MDATO/OSM cells to recombinant human OSM (hOSM), conditioned media (CM) from
MDATO/OSM cells treated with TET (0.1 µg/mL) was collected. MDA-MB-231, MDAMB-231-Luc, and T47D breast cancer cells were treated with either CM from
MDATO/OSM cells or with rhOSM (25 ng/mL) for 30 minutes. OSM signaling was
assessed by measuring STAT3 activation using a pSTAT3 ELISA. For each cell line
investigated, there were no significant difference in the level of pSTAT3 induced by
OSM produced from TET-induced MDATO/OSM cells compared to rhOSM (Fig 2A).
Furthermore, the CM from MDATO/OSM cells treated with TET was assessed on a hOSM
immunoblot and an expected size band (26 kDa) was detected (Fig, 2A, inset).
To assess the activity of MDATO/OSM cells in vivo, 1 x 106 cells were injected into
the 4th mammary fat pad of female athymic nude mice. The mice were given drinking
water with tetracycline (+TET) or without tetracycline (–TET) (0.1 mg/mL in 2% sucrose
water) to induce OSM expression in the cancer cells. At the experimental endpoint, their
serum was then separated from whole blood, and serum OSM levels were assessed by
ELISA. Tumor bearing mice +TET had a 67-fold higher level of OSM levels present in
their serum than –TET mice (Fig 2B, left). Each animal’s physical condition was
assessed, and animals with MDATO/OSM tumors +TET had significantly increased blood
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platelet counts (Fig. 2B, center). TET-treated mice also experienced a significant
decrease in body weight compared –TET mice (Fig. 2B, right; sFig. 1A), displaying a
prominent spinal column and reduced apparent body fat indicative of cachexia (sFig. 1B).
In the literature, it has been reported that cachexia, elevated inflammatory factors, and
kidney disease may be correlated with each other (44, 45), and in this study, the cachexic
animals had kidney abnormalities with hypoperfusion and damage to the gross
morphological kidney structures (sFig. 1C). This correlated with +TET treatment and
high levels of serum OSM in the animals (sFig.1D and E), which suggest that high OSM
levels may contribute to the development of cachexia and kidney organ dysfunction.
Additionally, in a separate experiment, animals were given TET drinking water
for only 1 week to assess early effects of OSM on metastasis. Animals on 1 week of
+TET had higher levels of metastases to the lung as assessed by ex vivo imaging
compared to –TET mice (Fig. 2C). This result suggests that even short-term elevation in
the level of OSM can promote the development of metastases. To measure animal
survival, mice with MDATO/OSM tumors were treated with or without TET and allowed to
progress to end point. +TET mice had a mean decreased survival of 11 days compared to
–TET mice (Fig. 2D). Collectively, these results demonstrated that elevated levels of
tumor cell-produced OSM lead to increased lung metastases, decreased survival, and
deterioration in body condition indicative of cachexia.
OSM increases metastasis to lung and circulating tumor cell numbers in an orthotopic
MDA-MB-231 model of breast cancer
To assess the paracrine effects of OSM, exogenous OSM was injected peritumorally in an orthotopic MDA-MB-231 xenograft model. In this model, 2 x 106 MDA-
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MB-231-Luc2 D3H2LN cells were injected into the fourth mammary fat pads of female
nude mice. After the tumors were palpable (~3 mm), OSM (1 µg in 50 L PBS) or PBS
alone was injected peri-tumorally 3 times per week, and mice were monitored until the
end-point criteria was met. Unexpectedly, tumor volume did not differ between the
groups (Fig. 3A), even though OSM has been shown to reduce MDA-MB-231 cell
proliferation in vitro (46). The BLI intensities of the tumors from both groups were
similar (Fig. 3B), although a few mice in each group had lower BLI intensities due to
tumor necrosis.
Mice receiving peri-tumoral OSM showed larger metastatic volumes in both lung
and spine compared to mice receiving PBS, as assessed by ex vivo imaging (Fig. 3C,
left). Additionally, lungs extracted from the OSM-injected group had luminescence
signals that were two orders of magnitude (102) higher than the PBS-injected group (Fig.
3C, right). Similarly, spine BLI intensity from OSM-treated mice averaged 2 x 107
photons/s, while control mice had a mean signal of 3 x 105 photons/s.
In patients with advanced and/or inflammatory breast cancer, high numbers of
circulating tumor cells (CTCs) have been detected, suggesting a correlation between
inflammatory factors and the number of CTCs (47). In our xenograft model, both human
MDA-MB-231-Luc2 tumor cells as well as potential CTCs contain multiple copies of
human Alu DNA repeat sequences. To assess CTC numbers, DNA was isolated from
mouse blood, and the levels of human Alu DNA repeat sequences were determined in the
blood by qPCR. In animals that received rhOSM injections, there was a 4-fold increase in
the number of CTCs per 100 µL of mouse blood compared to animals that did not receive
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OSM (Fig. 3D). Collectively, this suggests that increased paracrine OSM in the tumor
microenvironment, increases metastasis to lung and spine while also increasing CTCs.
Suppression of OSM in syngeneic mouse model reduced lung metastases
To utilize an immunocompetent mouse model, we utilized two highly metastatic
4T1.2 mouse mammary tumor cell lines exhibiting knockdown expression of OSM in a
syngeneic, orthotopic model of breast cancer (17). These two independent cell lines
(4T1.2-shOSM1 and 4T1.2-shOSM2) were shown by ELISA to secrete a 3- to 12-fold
reduction in OSM, respectively, as compared to control 4T1.2-LacZ cells (17). To test the
effects of OSM on mammary tumor metastasis in vivo, 1 x 105 control 4T1.2-LacZ,
4T1.2-shOSM1, and 4T1.2-shOSM2 cells were injected orthotopically into the mammary
fat pads of female Balb/c mice.
The mean number of relative lung metastases was shown to be 10-fold lower in
mice that received 4T1.2-shOSM1 cells and 5-fold lower in mice injected with 4T1.2shOSM2 cells, compared to 4T1.2-LacZ control cells (Fig. 4DA). Histology performed
on tissues from mice injected with parental 4T1.2 cells using an anti-mouse OSM
antibody showed strong OSM expression in the primary mammary tumor as well as some
background expression in the normal breast connective tissue (sFig. 2). Specifically, very
high OSM expression is shown at the leading edge of the primary tumor metastasis, in
closest proximity to the breast stroma.
Magnetic resonance imaging (MRI) was used to track lung metastases progression
in vivo after injection of parental 4T1.2, control 4T1.2-shLacZ, and 4T1.2-shOSM2 cells.
Mice were imaged post-injection at days 20-21, days 25-26, and just before sacrifice of
animals at days 29-30 (Fig. 4B). For all three cell lines, MRI images showed essentially
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no detectable metastasis at days 20-21. At 25-26 days and 29-30 days; however, readily
identifiable metastases were observed in lung images. The number of metastases was
reduced by more than 50% in mice injected with 4T1.2-shOSM2 cells compared to
control 4T1.2-shLacZ control cells at 25-26 days and 29-30 days (Fig. 4B and C). The
average metastasis volume was also significantly decreased by 50 to 80% in 4T1.2shOSM2 cells compared to 4T1.2-shLacZ control or parental 4T1.2 cells, respectively
(Fig. 4D). Thus, the in vivo MRI imaging confirmed that OSM is a potent inducer of the
metastatic cascade that ultimately results in lung metastases originating from a primary
mammary tumor. In total, these results suggest that OSM is necessary for spontaneous
mammary tumor metastasis to lung in a syngeneic mouse model.
Suppression of OSM by shRNA increases survival from spontaneous metastasis via
orthotopic injection but not via intracardiac injection in vivo
We utilized a tumor-resection survival model to mimic surgical removal of the
primary tumor in patients and to determine if suppression of tumor-produced OSM limits
early metastases. Orthotopic mammary fat pad injections were performed using control
4T1.2-shLacZ cells, 4T1.2-shOSM1, and 4T1.2-shOSM2 cells. Primary tumors were
resected when they became palpable at day 14 (Fig. 5A), and mice were monitored until
endpoint criteria were met (see Materials and Methods). The mean survival time of the
mice that received 4T1.2-shOSM1 and 4T1.2-shOSM2 cell injections significantly
increased by 5 and 10 days compared to animals with 4T1.2-shLacZ tumors (Fig. 5A).
These results suggest that following primary mammary tumor resection, decreased OSM
expression in primary tumor cells leads to increased survival.
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In order to determine if OSM affects post-intravasation aspects of metastasis, we
injected the mammary tumor cells directly into the circulatory system via the left
ventricle of the heart. There was no statistical difference in the survival time between
mice injected intracardially with 4T1.2-shLacZ versus 4T1.2-shOSM2 cells (Fig. 5B).
Similarly, there was no statistical difference in lung metastatic burden in the two different
tumor types as assessed by qPCR (sFig 3). These results suggest that tumor cell OSM
expression has little effect on post-intravasation aspects of metastasis to lung, such as
extravasation and metastatic site implantation.
CTC number and metastatic burden is reduced in OSM knockout mice compared to wild
type mice
To determine if knocking out OSM in the whole organism affects CTC numbers
in the 4T1.2 mouse model, wild type and OSM knockout (KO) Balb/c mice were
orthotopically injected with either 4T1.2-shLacZ or 4T1.2-shOSM2 cells. Whole blood
was collected at endpoint, red blood cells were lysed, and the remaining white blood cells
containing the epithelial CTCs were examined using a Clonogenic assay (Fig. 5C). Blood
from OSM KO mice injected with 4T1.2-shOSM2 cells had 15-fold less CTCs and 2.5fold less lung metastases compared to wild type mice injected with control 4T1.2-shLacZ
cells (Fig. 5D, left). Additionally, OSM KO mice bearing 4T1.2-shLacZ tumors had 10fold less CTCs and 2.5-fold less lung metastases compared to wild type mice with the
same tumor type (Fig 5D, right). These results suggest that microenvironment OSM,
independent from the tumor cell secreted OSM, has a large effect on tumor cell
dissemination into circulation. Furthermore, this highlights the importance of paracrine
OSM in breast cancer progression and metastasis.
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OSM increases pre-intravasation metrics of metastatic capacity in 4T1.2 cells
In order for tumor cells to enter the blood stream as CTCs and subsequently
metastasize, it is thought that they must first undergo an EMT, followed by detachment,
migration, and intravasation into the circulatory system (48, 49). To assess OSM’s effect
on EMT, detachment, and migration, mesenchymal-like triple negative (ER-, PR-, HER2) 4T1.2 mouse mammary cancer cells were treated with OSM (25 ng/mL) for 24 to 48
hours. As 4T1.2 cells are an aggressive mesenchymal mammary cancer cell type, OSM
did not affect their cell morphology nor produce an EMT, (Fig. 6A). On the other hand,
OSM significantly increased 4T1.2 mammary tumor cell migration 7-fold by day 3 in a
cell migration assay (Fig. 6B) and tumor cell detachment 100-fold by day 8 (Fig. 6C).
Our previous studies also demonstrated that OSM increases overall invasive potential in
4T1.2 cells (17). Together, these results suggest that OSM may promote tumor cell
dissemination into circulation by increasing cell migration and detachment, which may
subsequently increase the number of CTCs.
Discussion
In this study, we show that OSM, whether acting in a paracrine fashion or
produced by breast tumor cells and acting in an autocrine manner, can potentiate preintravasation metastatic events such as migration, detachment, and increased CTCs (Fig.
7). Recent studies suggest that cells from breast ductal carcinoma in situ (DCIS) can
actually metastasize prior to their development into malignant invasive ductal carcinoma
(IDC), though what triggers this early event has not been well characterized (50, 51). Our
breast cancer immunohistochemistry studies using tissue microarrays resulted in an
intriguing finding; OSM expression is highest in the epithelium of DCIS, as compared to
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IDC, metastatic, or adjacent normal tissue. However, García-Tuñón saw higher levels of
breast tissue OSM and OSMR in IDC than in DCIS or normal tissue (13). While there is
disagreement in the literature compared to our study in relation to the stage in which the
highest level of OSM was seen, there is agreement in so far as higher OSM levels were
detected in cancerous tissue versus normal tissue.
In this study, three different TNBC mouse models were utilized, one
immunocompetent Balb/c model using syngeneic 4T1.2 cells, and two
immunosuppressed athymic xenograft mouse models using either MDA-MB-231-Luc2 or
MDATO/OSM cells. Despite the differences between the systems used in our study, our
results were consistent in that suppression of OSM reduced metastasis in Balb/c mice and
injection of recombinant hOSM or TET-induced hOSM expression in MDATO/OSM cells
increased human breast tumor metastasis in athymic mice. Although, adaptive immunity
is stunted in athymic mice due to nonfunctional T-cells, innate immune function is still
intact (52). Recent studies indicate that innate immunity plays a primary role in
controlling progression of tumor growth and metastatic disease (53, 54), and innate
immune cells such as macrophages home to hypoxic tumors and promote angiogenesis
(19). OSM has recently been shown to increase lung metastatic burden in melanoma by
increasing M2 macrophage infiltration (55). Thus, OSM may be promoting inflammatory
responses mediated by innate immunity in the tumor microenvironment of both athymic
and Balb/c mouse models to promote metastases.
While the traditional cause of mortality in advanced cancer patients is metastasis
to vital organs, cachexia has been shown to contribute in up to 50% of cancer patient
deaths (56, 57). Significant weight loss as a consequence of fat loss and muscle wasting,
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indicative of cachexia, was seen in our TET-induced OSM in MDATO/OSM xenograft
mouse model. Other studies have shown that high levels of various inflammatory
cytokines such as IL-6, and tumor necrosis factor alpha (TNFα) potentiate loss of adipose
tissue and muscle wasting (58, 59). This suggests that OSM may be yet another cytokine
that could exacerbate cachexia in breast cancer patients. Furthermore, since cytokines
modulate the immune system, it’s very probable that cancer cachexia could be related to
maladaptive immune responses (60).
Platelets, as an adjunct to their classical role in thrombosis, are also operant in
mediating inflammation and immune response (61, 62). Interestingly, we found in the
MDATO/OSM mouse model that higher OSM levels were correlated with increased platelet
counts and reduced animal survival. Previous studies in breast cancer patients have
shown that elevated platelet counts were associated with poor prognosis and reduced
disease-free survival (63). Platelets have also been implicated in the promotion of
metastasis by acting as a reservoir for factors that induce invasion and function to protect
CTCs from the immune system (64, 65). In our study, increased viable CTCs were
detected in our mouse models when higher levels of OSM were present, which may have
been due, in part, to the elevated levels of platelets in circulation.
The ability of tumor cells to intravasate into the circulation directly correlates
with CTC numbers from the corresponding tumor (66). Increased CTC numbers have
been linked clinically to enhanced metastatic burden in patients and a reduced 5-year
survival rate (67). As tumors may shed early during cancer development (50), the
detection of CTCs would be an important tool in the clinic to assess the metastatic
capacity of a tumor, even as early as in precancerous DCIS. Typically, CTCs are detected
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using cancer epithelial markers such as cytokeratin (CK) 18/19 (68). However, highly
aggressive tumor cells that have already undergone an EMT, and thus lost their epithelial
markers, may evade detection (69, 70). Other possibly viable markers for CTC detection
include, epithelial cell adhesion molecule (EpCAM) or human mammoglobin A (hMAM)
(68). For our studies, the highly aggressive mesenchymal-like MDA-MB-231 cells show
negative or low expression for each of these markers, making conventional CTC
detection unfeasible (69, 71). Thus, we employed multiple techniques that are markerindependent, such as the Colony forming assay or a PCR assay targeting human Alu
sequences in human breast tumor cells growing in a mouse. In our studies, suppression of
tumor-produced OSM or the absence of OSM in OSM KO mice resulted in reduced
numbers of CTCs, while injection of recombinant OSM increased CTCs. Interestingly,
there was no significant difference in the number of CTCs +/-TET in the MDATO/OSM
mouse metastasis model (data not shown). This suggests that paracrine OSM may be
more important than autocrine-produced OSM for CTC development. Indeed, in our
OSM KO mouse model, where there is less paracrine OSM, total CTC numbers and lung
metastatic burden were significantly reduced compared to WT mice.
To assess some of the early aspects of metastases that could lead to generation of
CTCs in vitro, tumor cell EMT, migration, and detachment were studied in the highly
aggressive 4T1.2 tumor model. The 4T1.2 mammary tumor cells, which are considered
analogues of high-grade human TNBC, have already undergone EMT and OSM did not
cause additional EMT-like effects (72). However, our results show that OSM does
increase cell migration, detachment, and invasion in the 4T1.2 cells (17), supporting the
idea that OSM operates in the pre-intravasation steps of metastasis. Other OSM-related
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factors such as transforming growth factor beta (TGF), IL-6, and interleukin-8 (IL-8)
may promote CTCs by increasing tumor cell invasion, detachment, and epithelial to
mesenchymal transition (EMT) (73, 74). Furthermore, these effects may be amplified in
vivo, as OSM possesses a proclivity to accumulate in the acidic ECM of the tumor
microenvironment (21).
Based on our findings, OSM may potentiate the pre-intravasation aspects of the
metastatic cascade to increase metastasis to the lung, and bone (17). This is evidenced by
the fact that intracardiac injection of 4T1.2 cells with reduced OSM (4T1.2-shOSM2)
into mice, which bypasses intravasation step of the metastatic cascade, did not result in
increased survival compared to control cells (4T1.2-shLacZ). Therefore, it is highly
probable that OSM functions before intravasation during cancer progression, but does not
appear to affect CTC survival, tumor cell extravasation, and secondary tumor growth.
Conclusions
The results from this study suggest that OSM increases lung metastases and CTC
numbers by acting on the early stages of metastasis. This provides a rationale for the
administration of anti-OSM therapeutics before tumor resection at the earlier steps of the
disease with the potential to improve overall breast cancer patient survival.
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Chapter Three: Figures

Figure 3.1.

OSM is highly expressed in DCIS and IDC
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Figure 3.1. OSM is highly expressed in DCIS and IDC.
A, To detect the presence of OSM in breast cancer tissue, histological microarrays
from 72 breast cancer patients were stained with human OSM antibody by
immunohistochemistry. Twelve patients had ductal carcinoma in situ (DCIS), 54 patients
had non-metastatic invasive ductal carcinoma (IDC), and 16 patients had IDC with
metastasis to lymph nodes (Table 1). Results show that normal adjacent tissue does not
express much OSM, but OSM is highly expressed in DCIS and IDC. Secondary antibody
alone does not produce any background signals. B, Intensity quantification of OSM
stained tissues. Mean staining intensity for DCIS (2.00) and IDC (1.66) tissues are
significantly higher than normal adjacent tissue (1.33) and metastatic tissue (1.24). There
is no statistical difference between normal and metastatic tissue. Data expressed as mean
+/- SEM *p<0.05, two-tailed t-test.
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Figure 3.2.

MDATO/OSM tumors increase metastasis and decrease survival
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Figure 3.2: MDATO/OSM tumors increase metastasis and decrease survival.
A, MDATO/OSM human breast cancer cells were treated with or without TET and
the resultant CM from the treated cells were applied to parental MDA-MB-231, MDAMB-231-LUC, and T47D cells. The activity of OSM accumulated in the CM was
compared to commercially obtained rhOSM (25 ng/mL). There is no significant
difference between OSM produced by MDATO/OSM versus rhOSM in relation to its ability
to induce pSTAT3. Inset, Western blot analysis depicting that CM produced by
MDATO/OSM cells stimulated with TET contains OSM. B, Left, Animals with MDATO/OSM
tumors were given drinking water with or without TET and the whole blood was
collected at experimental endpoint. After allowing the blood to clot and serum separated
by centrifugation, the resultant serum OSM levels were measured by ELISA, and animals
with MDATO/OSM tumors with drinking water containing TET have 67-fold higher OSM
levels. B Center, Platelet counts are higher in MDATO/OSM tumor bearing mice +TET
compared to –TET mice. B Right, MDATO/OSM tumor bearing mice +TET have lower
bodyweight compared to mice –TET. C, Animals with MDATO/OSM tumors were given
drinking water containing TET for 1 week and their lung metastatic levels were assessed
by ex vivo bioluminescent imaging. C Left, Representative image of ex vivo
bioluminescent image. C Right, Average radiance analysis of the ex vivo bioluminescent
imaging in photons per second per cm2 per square radian (p/s/cm2/sr). Animals with
MDATO/OSM tumor +TET have a 5-fold higher bioluminescent radiance compared to –
TET mice. (–TET n=3, +TET n=6) Data expressed as mean ± SEM. D, Kaplan-Meier
survival curve for mice with MDATO/OSM tumors +/- TET. Mice that did not receive TET
have on average, 11 days longer survival (-TET n=9, +TET n=10) *** p<0.001 log-rank
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test. Data expressed as mean +/- SEM *p<0.05, **p<0.01, ***p<0.001, two-tailed t-test
or one-way ANOVA with Tukey’s post-test where appropriate.
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Figure 3.3.

Peri-tumoral OSM injections into mice with MDA-MB-231-D3H2LN
tumors promotes the development of metastases and CTCs
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Figure 3.3. Peri-tumoral OSM injections into mice with MDA-MB-231 D3H2LN tumors
promote the development of metastases and CTCs. A, The timeline shows orthotopic
MDA-MB-231 D3H2LN human breast tumor cell injection at day 0, peri-tumoral OSM
or PBS injections beginning 3X per week at day 13, and final day of sacrifice of both
groups at day 61. Average tumor volume (mm3) does not differ between the peritumorally injected OSM and PBS control groups. B, Representative images of PBS and
OSM injected tumor-bearing mice imaged ventrally by BLI. There is no statistical
difference between the groups and recapitulates results seen in A. C left, Representative
ex vivo BLI of lungs and spine from mice bearing MDA-MB-231 D3H2LN luc2 tumors,
which were treated with peri-tumoral injections of PBS or OSM. C right, Ex vivo BLI
intensities were quantified in the lung and spine. Lungs from mice receiving peri-tumoral
OSM injections show a 37.9-fold higher BLI intensity as compared to PBS injections,
and spines from mice injected with OSM also show an approximately 25.9-fold increase
over mice with PBS injections. Data expressed as photon/s (mean ± SEM; n=5-6). D,
Human CTCs containing human Alu DNA were detected from mouse blood by qPCR. In
animals that received OSM injections, there is a 4-fold increase in the number of CTCs
compared to controls. Data expressed as mean +/- SEM *p<0.05, two-tailed t-test.

127

Figure 3.4. Reduced OSM expression results in fewer spontaneous lung
metastases and lower total volume of lung metastases by MRI
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Figure 3.4. Reduced OSM expression results in fewer spontaneous lung metastases and
lower total volume of lung metastases by MRI.
A, Lung metastatic burden was quantified by qPCR. Mice bearing mouse
mammary 4T1.2-shOSM1 or 4T1.2-shOSM2 tumors have less metastasis to lung
compared to mice with 4T1.2-shLacZ tumors. B, Mice bearing 4T1.2-shOSM2 tumors
have less metastatic lesions in the lung as detected by MRI at the endpoint of the
experiment compared to mice bearing parental 4T1.2 or control 4T1.2-shLacZ tumors. C,
MRI quantification of lung metastatic volume, and D, total number of lung metastases,
shows significantly higher volume and number of lung metastases in the 4T1.2 or 4T1.2shLacZ injected mice as compared to the 4T1.2-shOSM2 injected mice. (4T1.2, n=6;
4T1.2-shLacZ, n=7; 4T1.2-shOSM2, n=7). Data expressed as mean ± SEM, *p < 0.05,
**p<0.01, one-way ANOVA with Tukey’s post-test.
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Figure 3.5.

Reduced tumor cell OSM expression increases survival in a 4T1.2shOSM mouse model of tumor resection
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Figure 3.5. Reduced tumor cell OSM expression increases survival in a 4T1.2-shOSM
mouse model of tumor resection.
A. The timeline shows orthotopic mouse mammary tumor cell injection at day 0,
resection at day 14, and final day of sacrifice per group (ranging from 35 to 72 days).
Kaplan-Meier survival analysis following tumor resection shows that mice bearing
4T1.2-shOSM1 or 4T1.2-shOSM2 tumors have significantly increased survival compared
to mice with control 4T1.2-shLacZ tumors. *p<0.05, log-rank test B, Timeline shows
intracardiac mammary tumor cell injection at day 0 and final day of sacrifice (day 21 to
22). Kaplan-Meier survival analysis shows no difference in survival between mice
injected with control 4T1.2-shLacZ versus 4T1.2-shOSM2 cells. C, Blood was collected
from wild type and OSM KO animals with 4T1.2-shOSM2 or control tumors and CTC
counts were assessed via a Colony forming assay. Representative image depicts higher
numbers of colonies that formed from the blood collected from wild type mice with
control tumors. D Left, Quantification of the colony formation assay show that wild type
animals bearing 4T1.2-shOSM2 tumors have 15-fold lower number of CTCs compared to
the animals bearing control 4T1.2-shLacZ tumors. Furthermore, OSM KO mice with
4T1.2-shLacZ tumors have 10-fold less CTCs compared to wild type mice bearing the
same cells. D Right, Wild type mice bearing 4T1.2-shOSM2 tumors have 2.5-fold lower
number of lung metastases compared to mice with control 4T1.2-shLacZ tumors. OSM
KO mice bearing 4T1.2-shLacZ or 4T1.2-shOSM2 tumors have 2- to 2.5-fold less lung
metastases compared to wild type mice. (4T1.2-shLacZ, n=8-9; 4T1.2-shOSM1, n=7;
4T1.2-shOSM2, n=9-12) Data expressed as mean ± SEM. *P<0.05, ***P<0.001, oneway ANOVA with Tukey’s post-test.
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Figure 3.6.

OSM promotes 4T1.2 cell detachment and migration
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Figure 3.6. OSM promotes 4T1.2 cell detachment and migration.
A, 4T1.2 mouse mammary cancer cells were plated and treated with rmOSM (25
ng/mL) for 24 and 48 hours, and no morphological changes indicative of EMT are
detected. B, 4T1.2 cells were grown to 80% confluency and a scratch was made. Cells
treated with OSM have higher levels of migration compared to untreated controls (7-fold
by day 3). C, A detachment assay was performed on 4T1.2 cells, and the number of
detached cells was quantified. Cells treated with OSM have significantly higher numbers
of detached cells (100-fold at day 8). Data expressed as mean ± SEM. *p<0.05,
***p<0.001 two-tailed student’s t-test.
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Figure 3.7.

Model of OSM-mediated metastasis

Figure 3.7. Model of OSM-mediated metastasis.
OSM is produced in an autocrine fashion by tumor cells A, and by tumorassociated macrophages and neutrophils for paracrine signaling B. OSM promotes preintravasation effects such as tumor cell detachment and migration that can drive tumor
cell intravasation into circulation to develop CTCs and eventual metastasis. C, When
tumor cells are injected directly into the circulatory system, they bypass the multi-step
pre-intravasation aspects of metastases, and our data suggest that OSM has little effect on
their extravasation and colonization at a secondary site.

134
Table 3.1

Comparison of OSM expression in the ductal epithelial cells of
different stages of ductal carcinoma of the breast (DCIS, IDC, and
metastatic tissues) and adjacent normal breast tissues.

Mean expression levels are statistically significantly different among the four stages.
Stage
No. of
Mean
95% Confidence
Pairwise comparison
patients
OSM
Limits
of stage means1
(Total no. of staining
cores)
Adjacent
50 (83)
1.33
(1.15,1.50)
A
Normal DCIS
12 (18)
2.00
(1.71,2.30)
B
IDC
72 (188)
1.66
(1.55,1.77)
B
Metastatic
16 (29)
1.24
(1.02,1.46)
A
1

Stages with the same letter are not statistically different; those with different letters are
significantly different at p<0.05.
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Figure 3.S1. Deterioration of body condition in MDATO/OSM tumor bearing mice
with TET
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Figure 3.S1. Deterioration of body condition in MDATO/OSM tumor bearing mice
treated with TET.
A, MDATO/OSM tumor bearing mice treated with tetracycline (+TET) lost on
average 11.4 % of their body weight during TET treatment, compared to –TET mice,
which gained on average of 5.5% of their body weight over the same time period. B,
Representative image of mice with MDATO/OSM tumors +TET shows prominent spinal
column, muscle wasting, and lack of visible adipose tissue. C, Gross morphology of
normal (left) and abnormal kidneys (right). Normal kidneys have a distinct border
between the medulla and the cortex, with the cortex shown as a darker pink/red color, and
the medulla shown as a lighter pink color. This indicates that normal blood perfusion was
taking place. Abnormal kidneys were both pale and hypoperfused (middle), or damaged
(right) with no clear distinction between the cortex and the medulla. D, One hundred
percent of mice in the +TET group have abnormal kidney morphologies, while only 25%
of the mice in the –TET group have abnormal kidneys. ** p<0.01 fisher’s exact test E,
Serum from mice with abnormal kidneys have a statistically higher level of OSM
compared to serum from mice with normal kidneys. Data expressed as mean ± SEM.
*p<0.05, **p<0.01, ***p<0.001 two-tailed student’s t-test.
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Figure 3.S2. OSM is highly expressed in orthotopic 4T1.2 primary mammary
tumors in female Balb/c mice
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Figure 3.S2. OSM is highly expressed in orthotopic 4T1.2 primary mammary tumors in
female Balb/c mice.
Histology using H&E confirms the presence of a large, primary mammary tumor
(T) 32 days after 4T1.2 mouse mammary tumor cell injection into the 4th mammary fat
pad of female Balb/c mice. High OSM expression is seen in the tumor, as is background
expression in the normal breast connective tissue (CT). OSM expression is shown to be
highest in the invasive edge of the tumor (T) closest to the normal breast connective
tissue (CT). Control slides with no primary OSM antibody show low background
staining.
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Figure 3.S3. qPCR analysis of lung metastases after intracardiac injections
Figure 3.S3. qPCR analysis of lung metastases after intracardiac injections.
4T1.2-shLacZ cells and 4T1.2-shOSM2 cells were injected through intracardiac
injection, and qPCR analysis of the lung metastases indicate that the difference between
the groups was not significant.
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Supplemental Materials and Methods
Complete details for tissue microarrays.
Breast tissue was obtained from paraffin block archives at the Department of
Pathology, Mercy Medical Center, Nampa, ID and removed of patient identity as per IRB
guidelines. Three tissue microarrays (TMA) of 1 mm thickness and totaling 72 patients
were made using a Quick-Ray, an instrument used for boring tissue from a paraffin block
(Woo-Ri Medic, Kent, WA). The TMAs were built in Dr. William Fyffe’s lab at
Northwest Nazarene University, Nampa, ID. Two blocks consisted of tissues from 54
breast cancer patients (32 adjacent normal, 9 DCIS patients, 54 IDC) without metastasis
and included three primary tumor cores and one adjacent normal core for each case. The
third block included samples from a total of 18 breast cancer patients (18 adjacent
normal, 3 DCIS, 18 IDC and 16 metastatic) with lymph node metastasis and contained
three primary tumor cores, two metastatic cores and one adjacent normal tissue core per
case. The TMAs included a row of control tissues including spleen, lung, placenta,
salivary gland, liver and brain. Spleen and salivary gland served as positive controls for
OSM staining.
Immunohistochemistry: The TMAs were stained for oncostatin M using the
Histostain Kit (Cat #95-9843; Invitrogen, Carlsbad, CA) per manufacturer’s instructions.
The TMAs were deparafinized using Histosol (National Diagnostics, Atlanta, GA) and
stained overnight with 1:400 dilution of rabbit anti-human OSM primary antibody (Cat
#sc-129; Santa Cruz Biotechnology, Santa Cruz, CA) and 1 hour with 1:1000 goat-anti
rabbit IgG-AP secondary antibody. TMAs stained with secondary antibody alone served
as the negative control, and spleen and salivary gland served as positive controls for
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OSM staining. The specificity of the ɑ-OSM antibody was tested by treating tissue
sections with 10 times the amount of OSM blocking peptide (Santa Cruz
Biotechnologies, Santa Cruz, CA) and incubating overnight at 40C. The mixture was then
diluted to the required concentration and immunohistochemistry was performed as above.
The TMAs were analyzed for OSM expression by an experienced pathologist, Dr.
Joseph Kronz, at Mercy Medical Center, Nampa, ID. The intensity of OSM staining in
the ductal epithelium was graded as follows: 0=No staining; 1=Light staining;
2=Medium staining; 3=Dark staining. In order to confirm reproducibility of the results,
the pathologist, Dr. Joseph Kronz, reread 10 TMA cores that were chosen at random, and
his observations were consistent with the previous results. In cases where a single core
had both cancerous and normal tissue, the OSM expression data in the cancerous part was
combined with other cancerous tissues. Similarly, the expression in the normal part was
combined with other adjacent normal tissues for statistical analysis.
Statistical analysis: Assessments from multiple cores for each patient were
averaged for epithelial cells and stage of malignancy (normal, DCIS, IDC, metastatic)
that was present in the core. These four stages were statistically compared among ductal
tissues. The OSM staining intensity was analyzed as a mixed model to accommodate
repeated observations on each patient. These repeated observations were assumed to have
non-negligible correlation and were modeled under standard repeated measures variancecovariance assumptions. Stage was treated as a fixed effect. Additionally, statistical
models considering patient prognostic markers were evaluated. These models included
the stage and the prognostic marker, with or without an interaction; the model with the
lowest AICc was selected to determine whether the prognostic factor was associated with
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OSM staining. These prognostic factors considered were age, tumor size, lymph node
status, angiolymphatic invasion, tumor grade, tumor type, histologic grade, nuclear
atypia, margin status, mitotic rate, Her2/neu expression, progesterone, and estrogen
receptor. Initial assessments indicated that OSM staining intensity did not differ
significantly between the two groups of patients (patients with and without lymph node
metastasis) so patient group was not included as an analysis factor in the study. All
models were assessed for adequacy by residual analysis, a concern here because of the
bounds on OSM staining intensity (0-3) and our specific interest in changes in mean
staining intensities. No predicted values exceeded the possible observational boundaries
and residual patterns were acceptable despite the categorical nature of the data collection.
All analyses were conducted using SAS version 9.1.3 (SAS 2004).
Animal Histology
To verify lung metastasis, lungs from each experimental group (4T1.2-LacZ, n=2;
4T1.2-shOSM2, n=2; and 4T1.2-shOSM1, n=1) were placed in ultralight fixative
(Ultralight Histology, Nampa, ID) paraffin embedded, and sectioned (Bi-Biomics,
Nampa, ID). For each spine, four 1 m sections were collected 10 m apart in the lumbar
region and H&E stained. The sections were then stained overnight with 1:400 dilution of
goat anti-mouse OSM primary antibody (Cat # AF-495-NA; R&D systems) and 1 hour
with 1:1000 donkey-anti goat IgG-AP secondary antibody. The sections were then
stained and imaged.
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Abstract
Inflammation is driven by various immunomodulatory cytokines such as
interleukin-6 (IL-6), oncostatin M (OSM), and interleukin-1 beta (IL-1β). Independently,
each of these cytokines can promote in vitro metrics of cancer metastasis such as tumor
cell detachment, epithelial-mesenchymal transition (EMT), and invasive potential.
Furthermore, these cytokines promote breast cancer metastases to distant organs in in
vivo mouse models. However, anti-IL-6 and anti-IL-1β therapeutics have not yielded
significant results against solid tumors in clinical trials. Only anti-OSM therapies remain
untested against human cancer progression. Here we show that these three cytokines are
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interrelated in function, which may explain why single anti-cytokine therapies have been
ineffective. Using Oncomine™ data, we have determined that there is a correlation
between high co-expression levels of OSM, IL-6, and IL-1β and reduced breast cancer
patient survival. Furthermore, we confirm that OSM induces the expression of IL-6 in
breast cancer in a manner that is dependent on both an estrogen receptor-negative (ER-)
status, as well as STAT3 signaling. In addition, OSM and IL-1β synergistically induce
IL-6 secretion using independent signaling pathways in MDA-MB-231 and MCF7 human
breast cancer cells. Specifically, OSM signals through STAT3 and ERK, while IL-1β
signals through p65 and ERK. This study demonstrates that OSM, IL-6, and IL-1β
expression levels in breast cancer patient data are correlated, suggesting a complex
interplay between these cytokines in tumor progression. Importantly, we provide a
rationale for a breast cancer treatment regime that simultaneously targets these three
proteins, as these cytokines appear to independently possess many overlapping functions
that increase metastasis and worsen patient survival.
Introduction
Breast cancer-related morbidity and mortality remains one of the top concerns for
women worldwide with 252,710 new cases of breast cancer predicted for 2017 (1).
Despite new treatments and extensive preventative screening initiatives, the breast cancer
incidence rate has remained flat, and there has been little improvement in the survival
rate for stage 4 metastatic breast cancer (2). Major breast cancer risk factors include
metabolic abnormalities and central obesity where there is extensive adipose tissue
accumulation in the midsection (3). Obesity incidence rates have been increasing in the
developed world and there are strong associations between obesity, cancer, and
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inflammation, suggesting increased rates of breast cancer with increasing obesity (4-7).
Inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha,
(TNF), and interleukin-1 beta (IL-1β) have been linked to tumor invasion and
metastasis (8). IL-6, in particular, has been associated with increased breast tumor cell
proliferation, metastatic capacity, and decreased patient survival rates (9). Although
recent research has shown the importance of IL-6 in cancer disease progression, anti-IL-6
therapies have not produced clinically beneficial results for the treatment of solid tumors
(10, 11). This suggests a redundancy where other pro-inflammatory mediators further
contribute.
The IL-6 cytokine is a part of the gp130 family of cytokines which include IL-6,
oncostatin M (OSM), leukemia inhibitory factor (LIF), IL-31, IL-11, IL-27,
cardiotrophin-1, ciliary neurotrophic factor, and cardiotrophin like cytokine (12). These
cytokines have a shared gp130 receptor subunit and have a wide range of functions in
cancer and inflammation (12-14). OSM, in particular, has been shown to induce tumor
cell detachment, invasion, EMT, induction of cancer stem cells, immune evasion, and
osteolytic bone metastases, (15-21). OSM is thought to exert much of its function through
binding to the OSM receptor (OSMR), a gp130/ OSMRβ complex, to induce downstream
signaling pathways such as signal transducer and activator of transcription 3 (STAT3),
mitogen-activated protein kinase (MAPK), and AKT (22-24).
OSM has been known to synergize with interleukin-1 (IL-1α) and IL-1β in the
context of cartilage breakdown in the joint, showing an amplified induction of matrix
metalloproteinases (MMPs), IL-8, as well as IL-6 (25-27). Additionally, OSM and IL-1β
have been shown to synergistically induce vascular endothelial growth factor (VEGF) in
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astroglioma cells (28). Both IL-1α and IL-1β activate the same IL-1 receptor, (a dimer of
IL-1R1 and IL-1RAcP), while IL-1α is a membrane bound protein and IL-1β is a soluble
protein (29). IL-1β increases tumor invasiveness, immunosuppression, and progression of
metastatic disease (29, 30). IL-1β is able to promote these effects through the activation
of p65 and ERK and induce the production of nitric oxide and proteinases (31-33).
Similar to our studies with OSM and breast cancer metastasis to bone (18), IL-1β also
stimulates the development of bone metastases (34). Unfortunately, anti-IL-1β therapies
such as anakinra (Kineret™) have not demonstrated significant effects against solid
tumors, although additional clinical trials are in progress to investigate its effectiveness
further (35-37). Together, these studies suggest that there are many overlapping functions
between IL-6, OSM, and IL-1β that expose possible weaknesses in the use of singular
anti-cytokine therapies.
Gene expression studies on breast cancer subtypes and immunological factors
such as TLR9, and signaling factors such as STAT3, MAPK, and AKT suggest that there
may be sub-type specific differences in the level of expression and activation of
downstream pathways (38, 39). This may inform that there are possible breast cancer
subtype specific differences in cytokine signaling, which would further complicate
possible therapeutic interventions using anti-cytokine biologics. Subtyping breast cancer
relies on the positive or negative detection of estrogen receptor (ER) and progesterone
receptor (PR), as well as the expression level of human epidermal growth factor receptor
2 (HER2) and Ki67 (40). Specifically, breast cancer cells that are classified as luminal A
(ER+/PR+/Her2low) are the less aggressive and have good prognosis overall, while triple
negative (ER-/PR-/Her2low) are much more aggressive (41). OSM have been shown to
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suppress ER expression in luminal A cells, and drive them into a more metastatic
phenotype (42, 43). In particular high expression of OSMR has been correlated with low
survival rates, which suggest that OSM signaling in general may promote breast cancer
progression (42). Other studies suggest that OSM may be higher in triple negative
compared to luminal A or B breast cancer phenotypes (44). Collectively, these studies
suggest that OSM expression and signaling may be correlated with breast cancer
subtypes, and that subtype specific breast cancer response to cytokines may drive breast
cancer disease progression.
In this study, we investigate the effect of OSM, IL-6, and IL-1β on breast cancer
patient survival as well as how these cytokines are interrelated in terms of cell signaling.
Using Oncomine™ data, we assessed the correlation between OSM and IL-6 with regards
to patient survival. Specifically, we found that high expression of OSM or IL-6 was
correlated to significantly decreased breast cancer patient survival. Furthermore, we
found distinct signaling differences between breast cancer subtypes in terms of OSM
induction of IL-6 in vitro with ER- MDA-MB-231 (ER-/PR-/Her2low), ER+ T47D
(ER+/PR+/Her2low), and ER+ MCF7 (ER+/PR+/Her2low) cells. Interestingly, OSM
induction of IL-6 only occurred in the ER- MDA-MB-231 cells through the STAT3
signaling pathway and not in the two ER+ cells lines tested. We also reveal that cotreatment of breast cancer cells with both OSM and IL-1β led to a synergistic increase in
IL-6 secretion. These results highlight that OSM and IL-1β synergistically increase IL-6
in breast cancer, promote a more metastatic phenotype, and reduce breast cancer patient
survival.
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Materials and Methods
Oncomine analysis
The Curtis human breast cancer mRNA microarray dataset (45) and the Finak
breast cancer stromal gene expression mRNA dataset (46) were obtained from
OncomineTM (Compendia Bioscience, Ann Arbor, MI). For survival analysis, the Curtis
dataset was filtered for “Invasive Ductal Carcinoma” and valid “Alive” or “Dead of
Disease” status. From the filtered dataset, upper (>75th percentile), and lower (<25th
percentile) quartiles of gene expression for OSM, IL-6, and IL-1β were selected for
comparison. For multi-gene co-expression analysis, we calculated for patients high in
both OSM and IL-6, or OSM and IL-1β. Survival statistical analysis was performed using
a log-rank test in Graphpad Prism 5 software.
To analyze gene correlations, the Curtis dataset was subjected to a correlation
analysis using Graphpad Prism 5 software and the RealStatistics package on Microsoft
Excel. To assess gene expression levels of OSM and IL-1β in stromal tissue, patients in
the Finak dataset were separated into normal and breast cancer categories, as well as into
ER+ and ER- breast cancer categories. Additionally, the Curtis dataset was also separated
into ER+ and ER- breast cancer categories to assess gene expression levels in the tumor
cells. Statistical analysis was performed using the 2-tailed student’s T-test in Graphpad
Prism 5 software.
Enzyme linked immunosorbent assay
Serum was collected from breast cancer patients of various stages at St. Luke’s
Mountain States Tumor Institute (MSTI) in accordance with the institutional review
board or purchased from Proteogenix (Schiltigheim, France) and Bioreclamations
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(Baltimore, Maryland). The serum was diluted 1:3 in PBS and used in the DuoSet ELISA
for IL-6 (DY206, R&D system) or for OSM (DY295, R&D systems) on Immulon HBX4
ELISA plates (3855, ThermoFisher) in accordance with the manufacturer’s instructions.
Data was analyzed using Graphpad prism 5.0 to determine correlations between OSM—
IL-6 serum concentrations.
Cells were incubated with OSM or IL-1β treatments (10 ng/mL) ranging from 4872 hours and the resultant cytokine levels were assessed. To measure human IL-6 and
OSM in conditioned media, the same R&D ELISA kits were utilized according to the
manufacturer’s instructions. Conditioned media from MDA-MB-231 cells were diluted
1:10 to 1:20 in order to accurately detect the amount of IL-6 within the range of the
standard. Conditioned media was collected from 24-well plates containing 1x 105 cells at
the time of cell plating.
Cell lines
MDA-MB-231, T47D, MCF7, and MDA-MB-468 human breast cancer cells,
PC3 and DU145 human prostate cancer cells, and HeLa human cervical cancer cells were
obtained from the American Type Culture Collection (Rockville, MD). All human cell
lines were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum
and to 100 units/mL of streptomycin and penicillin (Hyclone, Logan UT). 4T1.2 mouse
mammary carcinoma cells were maintained in MEM-alpha media supplemented with
10% fetal bovine serum and to 100 units/mL of streptomycin and penicillin. All cells, and
experimental incubations were maintained at 37oC, 5% carbon dioxide, and 100%
humidity in a water-jacketed cell culture incubator.
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Stable and transient transfections
To generate stably transduced MDA-MB-231 Luc2 D3H2LN cells (Caliper Life
Sciences) with inducible expression of OSM, the OSM cDNA (862 bp) (A generous gift
from Dr. Atsushi Miyajima, The University of Tokyo) was cloned into the pLenti
6.3/TO/V5-DEST vector (A11144 ThermoFisher). The vector+hOSM was then cotransduced with pLenti3.3/TR (A11144, ThermoFisher) into MDA-MB-231 Luc2
D3H2LN cells using the ViraPower™ II Lentiviral Gateway® Expression System
(K367-20, Life technologies) using the manufacturer’s instructions. Stably transduced
cells were injected into mice and resultant tumors and animal sera tested for TET
induction by western blot and ELISA. The stable TET inducible OSM expressing MDAMB-231 Luc2 D3H2LN clone has been designated as MDATO/OSM.
To generate stable expression of estrogen receptor alpha (ERα) in ER- MDA-MB231 cells, an ERα expressing plasmid (Cat# 28230, AddGene) was stably transfected into
MDA-MB-231 cells using Lipofectamine LTX (Cat# 15338100, Life Technologies). For
control cells, an empty pEGFP-C1 (Cat#6084-1, Clontech) vector was stably transfected
into these cells. Cells were transfected at 80% confluency in 96-well plates containing
RPMI 1640+10% FBS with 6 µg DNA per well and a lipofectamine:DNA ratio of 1.35:1.
Transfected cells were selected for using G418 at a concentration of 500 μg/mL.
Surviving colonies were expanded under antibiotic pressure and their expression of ERα
was verified by western blot analysis.
To transiently suppress STAT3, a siRNA pool targeting STAT3 was purchased
from Dharmacon (Cat #L-003544-00-0005). 100,000 cells per well were seeded in a 24well plate, and the siRNA was transfected in accordance to the Fast-Forward protocol as
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per the technical manual included with the Hyperfect siRNA transfection reagent (Cat#
301705, Qiagen). STAT3 siRNA was used at 25 nM and the cells were transfected for 72
hours before being treated with OSM or IL-1β. Knockdown of STAT3 was assessed by
western blot.
Animal tumor xenograft model
Six-week old female athymic nude mice were purchased from the NCI Animal
Production Facility (Fredrick, MD). The MDATO/OSM cells were grown to 90%
confluency and the cells were concentrated to 4.0 x 107 cells/mL in PBS containing 10%
RPMI 1640, and 50 uL of the cell suspension was injected into the 4th mammary fat pad.
When the tumors became palpable, the animals were given drinking water containing
tetracycline in 2% sucrose water for one week with doses ranging from 0 mg/mL, 0.1
mg/mL and 1 mg/mL. Animals were sacrificed and their serum and tumors collected for
analysis.
Immunoblot assay
Cells were plated on 24-well plates at 70-80% confluency and allowed to adhere
overnight at 37 oC. Cells were treated with cytokines, OSM (CAT#300-10T) and/or IL1Beta (CAT# 200-01B) (Peprotech), and with inhibitors, the ERK inhibitor PD98059
(CAT# 9900, Cell Signaling) or the p65 inhibitor caffeic acid phenyl ester (CAPE)
(CAT# 2743, Tocris). Cells were treated for 30 minutes or 72 hours. Conditioned media
was collected from the cells treated for a 72 hours, and cell lysates were collected from
both time points using 1x RIPA buffer containing a protease inhibitor cocktail (Sigma
Aldrich, CAT# P8340). Lysates were run on an SDS-PAGE gel and transferred to
nitrocellulose immunoblot membranes via semi-dry transfer. Blots were rinsed in ddH2O
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and allowed to completely dry before being blocked with PBS-T (PBS, pH 7.4; Tween20,0.05%; 5% non-fat dry milk) for 1 hour. After 3 x 5 min PBS-T washes, primary
antibodies (1:1000) suspended in PBS-T complemented with 1% BSA were then applied
to the membrane and incubated overnight at 4oC. After another 3 x 5 min PBS-T washes,
horse radish peroxidase conjugated secondary antibodies suspended in PBS-T were then
applied to the membrane. Then with a final 5 x 5 min PBS-T wash, the membrane was
developed with enhanced chemiluminescence and imaged using Syngene G:BOX imager.
All antibodies used for the immunoblots were acquired from Cell Signaling
Technologies. STAT3 (CAT#9132), phospho-STAT3 (Y705) (CAT# 9145), Beta-Actin
(CAT#3700), NFκB p65 (CAT#8242), phospho-NFκB p65 (CAT#3033), phospho-ERK
(CAT# 4370), Anti-rabbit IgG-HRP (CAT# 7076).
Immunoprecipitation
MCF7 and T47D cells were incubated with 10 ng/mL of OSM and/or IL-1β for
48 hours at a density of 100,000 cells per well in a 24-well plate. Cells were lysed with
Cell Signaling PathScan® Lysis buffer (Cat# 7018) using the manufacturer’s
instructions. The lysates were then used on a Dynabeads® Protein A
Immunoprecipitation Kit (Cat# 10006D, Life Technologies) using ERα IP antibody at
1:50 dilution from Cell Signaling (Cat# D8H8) in accordance with the kit instructions
with the following modification. In order to reduce co-elution of the antibody, the
antibody was cross-linked using 20 mM dimethyl pimelimidate dihydrochloride (Cat#
21666, Pierce) in 0.2 M triethanolamine at a pH of 8.2. The antibody-bead complex was
cross-linked for 30 minutes, and the reaction was stopped by resuspending the beads for
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15 minutes in 50 mM pH7.5 Tris. The beads were then used in the rest of the
immunoprecipitation protocol following a 3x PBS-0.05% Tween-20 wash.
Statistical analysis
All the statistical analyses were performed using GraphPad Prism version 5
software or with the RealStatistics™ package for Microsoft Excel. To compare multiple
groups, one- or two-way ANOVA was performed using Tukey’s post-test where
appropriate. Comparisons between two groups were assessed by unpaired two-tailed
student’s t-test. Correlations were assessed using the Spearman nonparametric correlation
analysis. Survival data was assessed using the Log-rank test. Statistical significance was
assigned to experimental p values that were less than 0.05. Error bars represent the
standard error of the mean unless otherwise specified, and all experiments were
performed at least three times.
Results
OSM and IL-6 expression are correlated with each other and associated with decreased
invasive breast cancer survival
Both OSM and IL-6 have previously been shown to increase breast cancer
metastatic potential in vitro as well as promote metastasis in vivo (9, 18, 22, 42, 47-51),
which suggests that these cytokines may negatively affect patient survival. In particular,
serum IL-6 levels have been correlated with reduced breast cancer patient survival (52).
To assess the relevance of tumor tissue expression of OSM and IL-6 in the context of
invasive breast cancer patient survival, we used the Curtis Breast dataset obtained from
Oncomine ™ (45). The upper quartile was delineated as the top 25% of patient
expression levels (high expression), while the lower quartile represents the bottom 25%
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expression (low expression). High tumor tissue expression of OSM (p<0.001, Fig. 1A)
and IL-6 (p<0.001, Fig. 1B) both correlated with a significant decrease in survival. As
this data demonstrates that OSM and IL-6 independently correlates with decreased
survival in invasive breast cancer patients, we next assessed whether co-expression of
high levels of OSM and IL-6 is also correlated with decreased survival. Indeed, high coexpression of both OSM and IL-6 were significantly correlated with decreased survival
compared to low co-expression of both OSM and IL-6 (p=0.0091, Fig. 1C). Further
assessment revealed that expression of OSM correlates with IL-6 with a Spearman
coefficient of 0.576 (p<0.0001, Fig. 1D). Collectively, this suggests that elevated breast
cancer tissue levels of OSM and IL-6 leads to decreased survival and that their expression
is correlated with each other. This kind of co-expression is indicative of potential coregulation and suggests that these cytokines may induce the expression of each other.
High OSM serum levels in breast cancer patients are correlated high IL-6 levels
Previous studies suggest that aberrant expression of growth factors and cytokines
in the tumor microenvironment (TME) can result in these proteins leaking into the
circulation and become detectable in patient serum (53, 54). To assess whether serum
concentrations of OSM and IL-6 also show a correlation, as seen with the Curtis Breast
dataset in Figure 1D, we assessed serum samples collected from breast cancer patients
and healthy individuals by ELISA. Breast cancer patient serum had significantly higher
levels of OSM and IL-6 compared to serum from individuals without malignancies (Fig.
2A, B). Next, we analyzed the serum sample data to test whether OSM serum
concentrations are correlated to IL-6 concentrations. In samples with no OSM, there was
very little IL-6 in the serum, while any serum sample with >0 pg/mL concentration of
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OSM had a significantly higher level of IL-6 (Fig. 2C). Furthermore, a serum OSM and
IL-6 concentration correlation analysis reveal that there is a Spearman coefficient of
0.3774 (p<0.0001, Fig. 2D). These results suggest that patients with breast cancer have
elevated serum OSM and IL-6 levels compared to normal patients and that the serum
concentrations of these cytokines correlate with each other similarly to the tumor
expression levels of OSM and IL-6 seen with the Curtis dataset.
OSM promotes IL-6 expression in a mouse model of human breast cancer
In order to recapitulate potential OSM-induced IL-6 expression in breast cancer,
we utilized an MDA-MB-231 orthotopic mouse model of human breast cancer. MDAMB-231-Luc2 cells were stably transfected with a TET-inducible OSM expression
vector, and these MDATO/OSM cells were orthotopically injected into athymic nude mice
into the 4th mammary fat pad. Once the tumors were palpable ~3-5 mm, the animals were
given drinking water with 2% sucrose containing 0.1 mg/mL tetracycline (+TET) or 2%
sucrose water alone (-TET). MDATO/OSM tumor bearing animals +TET had a 32-fold
higher expression of OSM in their tumors compared to –TET tumors (Fig 3A) and 10.8fold higher IL-6 expression level (Fig 3B) as measured by western blot analysis. After
collecting blood, OSM and IL-6 serum levels were assessed by ELISA. TET- treated
mice had higher levels of OSM (9.8-fold, Fig 3C Left) and IL-6 (96-fold, Fig 3C Right)
in their serum, and the concentrations correlated with each other with an r2 coefficient of
0.9058 (p=0.0034, sFig 1). Collectively, TET induction in these mice led to increased
levels of OSM and IL-6 in both the tumors and serum, which concurs with the breast
cancer patient serum data and the Curtis breast cancer tumor expression data from
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Oncomine. This also suggests that elevated cytokine serum levels may be indicative of
high cytokine expression levels in the tumor microenvironment (TME).
OSM induces human IL-6 secretion in the absence of ER from various cancer cells in
vitro
Our results indicate that there is strong inter-correlation between OSM and IL-6
expression and secretion levels in breast cancer. To assess the nature of cytokine
production in breast cancer cells, various cell lines including two human ER+ cell lines,
T47D and MCF7, and three ER- cell lines MDA-MB-468, MDA-MB-231, and 4T1.2
mouse mammary cancer cells were treated with OSM, and their IL-6 secretion was
assessed. In addition, PC3 and Du145 human prostate cancer cells as well as HeLa
human cervical carcinoma cells were tested for OSM-induced IL-6 secretion.
Recombinant hOSM (25 ng/mL) was used to treat the human cell lines, while
recombinant mouse OSM (rmOSM; 25 ng/mL) was used for the 4T1.2. The cells were
treated with OSM for 48 hours, and IL-6 levels in the conditioned media (CM) were
assessed by ELISA. Interestingly, OSM did not induce IL-6 secretion in the ER+ MCF7
or T47D cells but did in the ER- cells (Fig. 4A). OSM promoted IL-6 secretion
approximately 5-fold in MDA-MB-468 cells, ~4-fold in MDA-MB-231 cells, and ~4-fold
in 4T1.2 mouse mammary carcinoma cells (Fig 4A). Androgen receptor-negative (AR-)
PC3 cells express high levels of IL-6 with or without OSM, while OSM induced IL-6
approximately 6.5-fold in the AR- Du145 cells (Fig 4B). Also in the ER- HeLa cells, IL6 levels were undetectable in the absence of OSM treatment, but the cells produced 1245
pg/mL of IL-6 with OSM treatment (Fig 4B). On the other hand, IL-6 had no effect on
OSM secretion in MDA, T47D, or MCF7 cells (sFig 2), which suggest that there is no
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reciprocal induction of cytokine secretion. These results show that OSM increased IL-6
expression in cells that are more aggressive and may correlate to estrogen receptor status.
To assess whether the presence of ER is essential for OSM induction of IL-6, ERMDA-MB-231 cells were stably transfected with an ER expression vector (pEGFP-C1).
Two independent colonies, MDAER+/C7, and MDAER+/H6, were shown to express ER by
western blot analysis (Fig 4C). Parental MDA-MB-231 cells, MDAER+/C7, and
MDAER+/H6 were treated with rhOSM (25 ng/mL) for 48 hours to assess their IL-6
secretion. The CM was then collected and their IL-6 concentrations were analyzed by
ELISA. MDAER+/C7 cells exhibited a 7.8-fold decrease and MDAER+/H6 cells demonstrated
a 12.1-fold decrease in the levels of IL-6 produced in response to OSM, as compared to
the parental MDA-MB-231 cells (Fig 4D). This result indicates that the ER+ MDA-MB231 cells have limited OSM-induced IL-6 expression and suggests that ER may play a
negative regulatory role in OSM signaling that leads to IL-6 expression.
STAT3 is phosphorylated by OSM signaling in both ER- and ER+ cells
Previous studies show that IL-6 induction is dependent on the activation of NFκB
and STAT3 signaling pathways (55). MDA-MB-231, T47D, and MCF7 were treated with
25 ng/mL OSM for 5 and 30 minutes to assess which signaling pathways are activated in
response to OSM in these cells. STAT3, AKT, ERK, and JNK pathways were activated
by OSM in all three cell lines, however only MDA-MB-231 cells produced IL-6 in
response to OSM (Fig 5A). This suggests that despite the nearly uniform activation of
OSM-induced pathways in both ER+ and ER- cells, there must be something else
occurring that is suppressing IL-6 production in the ER+ cells. Further investigation
using siRNA (20 nM) against STAT3 completely abrogated OSM-induced IL-6 secretion
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in MDA-MB-231 cells as detected by immunoblot (Fig 5B) and ELISA (Fig 5C), thereby
implicating STAT3 as the primary signaling pathway responsible for OSM induction of
IL-6 secretion. This also demonstrates that STAT3 is not able to induce IL-6 expression
in ER+ T47D or MCF7 cells despite the apparent phosphorylation of STAT3 by OSM.
Invasive breast cancer patient stroma expresses high levels of OSM and IL-1
IL-1β has been known to synergize with OSM in the context of inflammatory
conditions such as arthritis and progressive joint deterioration (25, 56) and has been
shown to induce the expression of IL-6 in vitro (57). As inflammation appears to have
negative effects on breast cancer patient survival, we assessed patient data related to these
cytokines. In particular, stromal cytokines in the breast cancer microenvironment appear
to play a major role in the progression of metastatic disease (58). We assessed OSM and
IL-1β stromal expression in both normal and invasive breast cancer patient data using the
Finak Breast Stromal dataset (46) obtained from Oncomine™. Stromal OSM expression
was 5.9-fold higher in invasive breast cancer compared to normal samples (Fig 6A), and
stromal IL-1β was 5.4-fold higher in invasive breast cancer compared to normal samples
(Fig 6B). There was also a significant increase in stromal OSM (sFig 3A) and IL-1β
expression (sFig 3B) in ER- samples compared to ER+ samples. Using the Curtis dataset,
a significant increase in tumor OSM expression (sFig 3C) as well as tumor IL-1β (sFig
3D) expression was seen in ER- samples compared to ER+ samples. These data suggest
that in breast cancer patients both paracrine and autocrine production of OSM and IL-1β
may work in an ER-dependent manner to affect patient survival.
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OSM and IL-1β promote increased lymph node metastases and decreased survival: a
three-way correlation for OSM-IL-1β-IL-6 expression
The correlation between tumor OSM and IL-1β expression and metastatic
capacity was assessed in the Curtis patient dataset. A 2.1-fold increase in lymph node
metastasis seen with high OSM versus low OSM expression for invasive breast cancer
(Fig 6C Left). Similarly, lymph node metastasis was higher in patients with high IL-1β
expression (Fig 6C Center). Furthermore, when both OSM and IL-1β co-expression was
high, there was also a significantly higher number of lymph node metastases compared to
the low OSM and IL-1β co-expression group (Fig 6C Right). High expression of OSM
and IL-1β also led to decreased patient survival (Fig 6D). In addition, OSM expression
levels correlated with IL-1β expression level (sFig 4A) and IL-1β expression levels
correlated with IL-6 expression level (sFig 4B). To determine whether all three cytokines
were correlated with each other, OSM, IL-6, and IL-1β expression levels were assessed
using a least squares multiple correlation analysis (Fig 6E). The three-way correlation
coefficient of OSM, IL-6, and IL-1β was 0.6001, with a p-value of 2.2 x 10-23, indicating
significant correlation between the three cytokines in this analysis. Collectively, these
results suggest that OSM, IL-6, and IL-1β are interrelated in breast cancer patient
metastasis and survival. These results demonstrate that not only does each one of these
cytokines increase metastasis and decrease survival in breast cancer patients but also
induce the expression of other cytokines as well. This may provide at least in part, an
explanation as to why clinical trials using single anti-cytokine therapies thus far have
failed.
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OSM works synergistically with IL-1 to promote IL-6 secretion
We have shown that high OSM, IL-6, and IL-1β levels all correlate with
decreased breast cancer patient survival, and that high expression levels of these three
cytokines correlate with each other in patient samples. Therefore, it is possible that OSM
and IL-1β may work synergistically to promote IL-6 expression and secretion. To better
assess the relationship between the two cytokines, we decreased the amount of OSM and
IL-1β used in the experiments from 25 ng/mL to 10 ng/mL, thus reducing the probability
of saturating the cell’s capacity to produce IL-6. Treating ER- MDA-MB-231 cells with a
combination of OSM and IL-1β for 72 hours resulted in a 44.8-fold increase in IL-6
secretion by ELISA, while OSM alone lead to a 6.4-fold increase and IL-1 alone lead to
a 17.3-fold increase compared to not-treated cells (Fig 7A). This suggests that OSM and
IL-1β induce IL-6 production in a synergistic manner in ER- cells. No induction of IL-6
secretion by OSM was seen in either ER+ T47D or MCF7 cells. After adjusting the scale
for IL-6 secretion levels, an increase in IL-6 secretion by IL-1 was seen in ER+ MCF7
cells, as compared to untreated controls (Fig 7B). MCF7 cells also exhibited a synergistic
24.8-fold increase in IL-6 secretion by treatment with both OSM and IL-1β compared to
IL-1β alone (Fig 7B). Although the level of IL-6 production is much lower in the ER+
MCF7 cells compared to the ER- MDA-MB-231 cells, there is a clear indication of a
synergistic relationship between OSM and IL-1β in this cell line as well. T47D cells, on
the other hand, were unable to produce any IL-6 in response to OSM or IL-1β, even
though their activity was confirmed by an increased EMT-like morphology and
invadopodia formation (sFig 5). This indicates that even if a breast cancer cell line like
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T47D is unable to produce IL-6 in response to OSM or IL-1β, it can still promote
invasive characteristics independently of IL-6 (20).
OSM and IL-1β activate separate signaling pathways to promote IL-6 production
The synergistic upregulation of IL-6 secretion in response to OSM and IL-1β
suggests that these cytokines may be using separate pathways to promote IL-6 in breast
cancer cells. Our data here and previously published work demonstrate that IL-1β utilizes
the NFκB pathway and OSM uses the STAT3 pathway to induce IL-6 production (55).
Interestingly, a past study indicated that there is crosstalk between STAT3 and NFκB to
promote downstream effects (59). To assess gross signaling pathway differences between
OSM and IL-1β on MDA-MB-231, T47D, and MCF7 cells, the cells were treated with
both cytokines (10 ng/mL) for 20 minutes (Fig 7C) or 72 hours (Fig 7D). In all breast
cancer cell lines tested, OSM specifically induced STAT3 phosphorylation, while IL-1β
induced p65 phosphorylation. This suggests that OSM may primarily induce IL-6
expression through STAT3 activation, while IL-1β induces IL-6 expression through the
activation of the NFκB pathway. Additionally, ERK phosphorylation was unaffected in
ER- MDA-MB-231 cells, but both OSM and IL-1β increased phospho-ERK in both
T47D and to a lesser extent, in MCF7 cells. This data hints that there may be some ERK
signaling related aspects to IL-6 secretion as both OSM and IL-1β affected ERK
phosphorylation. To investigate the involvement of the ERK pathway, a small molecule
inhibitor against ERK (PD98059) was used (sFig 6A). While MDA-MB-231 cells were
unaffected by ERK inhibition (sFig 6B), IL-1β and OSM+IL-1β induced IL-6 secretion
in MCF7 cells was significantly reduced (sFig 6C). Therefore, IL-1β-mediated induction
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of IL-6 in MCF7 cells may utilize the ERK signaling pathway in addition to the NFB
pathway, while only the NFκB pathway is used in MDA-MB-231 cells,
Another signaling difference between the cell lines was that OSM-induced
STAT3 phosphorylation was much weaker in MCF7 cells compared to T47D or MDAMB-231 cells (Fig 7C and D). This could suggest that IL-6 induction by OSM and IL-1β
might not be dependent on STAT3 activation in MCF7 cells unlike with MDA-MB-231
cells. To confirm that IL-1β does not signal through STAT3 to induce IL-6, STAT3
siRNA was used in the OSM+ IL-1β co-treatment experiment. In the MCF7 cells, STAT3
siRNA did not affect IL-1β-induced IL-6 levels (sFig 7). However, OSM-induced IL-6
was suppressed by STAT3 siRNA in MDA-MB-231 cells, and with the OSM+IL-1β cotreatment, IL-6 levels were lower compared to control siRNA levels. Additionally,
caffeic acid phenyl ester (CAPE), a p65 inhibitor, suppressed OSM induction of IL-6 in
MDA-MB-231 cells despite OSM’s inability to activate p65 phosphorylation (sFig 8).
This may suggest some type of crosstalk occurring between STAT3 and NFκB signaling
pathways in MDA-MB-231 cells (59). Overall, these results indicate that there are minor
differences between cell lines in terms of intracellular signaling activation in response to
OSM and IL-1β, and suggest that there may be a mechanism of IL-6 suppression that is
independent of phosphorylation in the ER+ cells.
ER interaction with STAT3 is suppressed by OSM and IL-1β in MCF7 cells
In other studies, ER has been known to directly interact with various signaling
molecules including p65 to suppress downstream signaling despite its apparent activation
by protein phosphorylation (60). To assess whether ER may be binding to intracellular
signaling pathway proteins, an immunoprecipitation with ER pull-down was performed
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on ER+ MCF7 and T47D cell lysates treated with OSM and/or IL-1β for 48 hours. While
no interaction between ER and p65, AKT, or ERK was observed (data not shown), a 50%
reduction in interaction between ER and STAT3 in response to OSM or IL-1β in MCF7
cells was seen using a STAT3 immumoblot of ERα-imunoprecipitation eluates (Fig 7E).
With T47D cells, no interaction between ER and any of the signaling proteins was
detected (data not shown). This suggests that the interaction of ER with STAT3 may
suppress OSM induction of IL-6 in MCF7 cells, and that in the ER+ T47D cells an
alternate mechanism may be operant. Collectively, OSM and IL-1β appear to induce IL-6
in a synergistic manner with OSM signaling through STAT3 and IL-1β operating through
p65 and ERK.
Discussion
Previous therapeutic interventions against inflammatory cytokines such as IL-6
have failed in clinical trials despite their well-known role in tumor and metastasis
promotion (9, 10, 12). Nevertheless, there has been renewed interest in mitigating
inflammation in the tumor microenvironment, as a growing recognition that chronic
tumor inflammation leads to angiogenesis, immunosuppression, proliferation, and
metastasis exists (61). Inflammatory cytokines such as OSM, IL-6 and IL-1β have
individually been shown to promote effects associated with metastatic cancer (9, 29, 62,
63). Here we show for the first time the interplay between the three cytokines in breast
cancer. We demonstrate that not only were the levels of tumor and stromal expression of
these cytokines correlated with metastatic disease and decreased patient survival, but that
there was an ER subtype-specific response in terms of OSM- and or IL-1β-mediated
induction of IL-6. Specifically, ER+ MCF7 and T47D human breast cancer cells failed to
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produce IL-6 in response to OSM, while high levels of IL-6 was produced with OSM
treatment in the ER- MDA-MB-231 cells. Other studies have shown that there are
subtype-specific differences in breast cancer’s response to IL-6 cytokines where the
magnitude of STAT3 pathway activation in response to IL-6 correlated to ER expression
(64, 65). Additionally, our results indicated that, OSM and IL-1β synergistically
increased IL-6 production by activating two separate pathways, STAT3 and NFκB, in
ER- MDA-MB-231 cells. This was also seen in the ER+ MCF7 cells, albeit at a much
lower level. Studies on arthritis and joint physiology have also demonstrated a synergistic
relationship between OSM and IL-1β in terms of joint damage and synovial fibroblastmediated inflammation (25, 56). We further showed that OSM induces IL-6 secretion in
the MDA-MB-231 cells through the STAT3 pathway, and that ER appears to inhibit
downstream STAT3 signaling (Fig. 8). Unlike in the ER+ MCF7 cells, which produced
IL-6 in response to IL-1β and OSM co-treatment, T47D cells did not produce IL-6 under
any conditions tested. This suggests that despite these two cell lines being the same
luminal A breast cancer cell subtype, there are major differences in their intracellular
signaling mechanisms. Additional studies are required to elucidate this difference as there
may be mechanisms independent of pathway activation via phosphorylation. Taken
together, this study highlights the complex interplay of various inflammatory cytokines in
a manner that is subtype specific.
Of the three cytokines studied in the paper, only therapeutic interventions
targeting IL-6 have received a lot of attention (9, 47, 66-68). Recent clinical trials using
an anti-IL-6 biologic, siltuximab, have failed to produce any clinically positive results in
the treatment of solid tumors (10, 11). Our results suggest that inflammation in the tumor
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microenvironment may be instigated by multiple cytokines and that IL-6 may only be a
part of the whole picture. Here, we have shown that OSM and IL-6 are correlated with
each other in patient serum data and in an in vivo mouse model of breast cancer
(manuscript in preparation). Additionally, we show that OSM, IL-6, and IL-1β levels are
correlated with each other in patient data, and that high levels of these cytokines lead to
reduced patient survival. To date, there are no anti-OSM therapeutics available, nor are
there any clinical trials in progress or planned to investigate anti-OSM therapies against
solid tumors. On the other hand, there are several anti-IL-1β (Anakinra) therapeutics
available that were developed for Castleman’s disease, where abnormally high levels of
inflammatory cytokines are produced by various immune cells (69, 70). While this antiIL-1β therapeutics appeared promising for the treatment metastatic disease (35), it failed
to produce significantly positive results in a colorectal cancer model (36). Additional
studies and clinical trials for anti- IL-1β therapeutics are underway to assess their antitumor capacity in other types of metastatic disease (37, 71, 72).
An interesting aspect of this study is that we demonstrated a breast cancer
subtype-specific difference in the production of IL-6 in response to OSM and/or IL-1β,
thus suggesting that subtype-specific markers like ER may play a role in this difference.
Previous studies have shown that induction of IL-6 expression is dependent on the NFκB
pathway and that ER suppresses this signaling through inhibition of p65 (60, 73).
However, our immunoprecipitation results suggest that ER may interact with STAT3 to
suppress OSM induced-IL-6 secretion. Furthermore, suppression of the STAT3 pathway
by siRNA also reduced OSM-induced IL-6 production to untreated control levels in
MDA-MB-231 cells. On the other hand, induction of IL-6 by IL-1β alone or by both
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OSM and IL-1β was not affected by STAT3 siRNA. Instead, IL-1β has been previously
shown to induce IL-6 expression through p65 and PI3K dependent pathways (57). Here,
we show that IL-1β induction of IL-6 is partially dependent on ERK signaling in MCF7
cells, as the usage of the ERK inhibitor suppressed IL-1β and IL-1β+OSM induction of
IL-6.
Our immunoprecipitation result in MCF7 cells also suggested that treatment of
the cells with OSM, IL-1β, or with both cytokines reduced the association of ER with
STAT3. Initially this seems to be an unusual result as IL-1β does not utilize the STAT3
pathway to induce downstream signaling. However there appears to be some measure of
cross talk between the STAT3 pathway and the p65 pathway, where in some cases the
function of the pathway may be interdependent on one another (74). We also saw
reduction in OSM induced IL-6 secretion from MDA-MB-231 cells with the use of the
NFκB inhibitor caffeic acid phenyl ester (CAPE) (75), despite OSM’s inability to activate
p65 phosphorylation. This suggests that there may be crosstalk between STAT3 and
NFκB for the induction of IL-6, and may explain the synergistic relationship between
OSM and IL-1β. While the exact nature of the crosstalk mechanism is not well known, it
appears that NFκB and STAT3 signaling proteins must be activated and directly bind to
each other during signaling (59, 74) (Fig. 8). However, if this is the case, STAT3 siRNA
should have inhibited IL-1β-mediated IL-6 secretion in MDA-MB-231 and MCF7 cells.
A possible alternative explanation is that ER forms an inhibitory complex with STAT3 to
suppress IL-6 expression, similar to the ER/p65 complex which is known to have a
regulatory role in gene expression (76). This would make suppression of total STAT3
ineffective for reduction of IL-6 expression, as doing so would also render the ER-
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STAT3 inhibitory complex less effective at regulating IL-6 gene expression. While we
have not been able to elucidate the exact mechanism of STAT3/ER interaction and the
crosstalk with NFκB, these results necessitate investigation into pathways that are not
necessarily canonically known to be activated by the specific cytokine. Therefore, further
investigation into the mechanistic nature of how these signaling pathways interact with
each other in the context of breast cancer is needed.
Conclusions
Collectively, our study demonstrates that OSM, IL-6, and IL-1β levels are
correlated with each other and that cytokine signaling differs in an ER subtype-specific
manner. This highlights the possible implications of multi-cytokine effects in the tumor
microenvironment and that singular anti-cytokine therapies may not be sufficient for the
successful treatment of metastatic breast cancer. This may be due to the fact that OSM,
IL-6, and IL-1β each work independently to impair breast cancer patient survival and
increase metrics of metastases. Thus, suppression of one cytokine may be countered by
an increase in a different but related cytokine to maintain the cancer metastatic potential.
Therefore, this study substantiates the rationale for a therapeutic design that
simultaneously targets multiple cytokines, such as OSM, IL-6, and IL-1β, as these
cytokines are strongly intercorrelated in breast cancer. In conclusion, we suggest that
further studies need to be done to unravel the complex interplay between these cytokines
and that future clinical trials should include the inhibition of multiple cytokines.
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Chapter Four: Figures

Figure 4.1.

OSM and IL-6 are associated with decreased invasive breast cancer
survival
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Figure 4.1. OSM and IL-6 are associated with decreased invasive breast cancer survival.
A, Kaplan-Meier curves of invasive breast cancer patient samples with high OSM
expression levels show significant reduction in survival compared to curves of patients
with low OSM expression levels. Log-rank test (p<0.0001) B, This trend is repeated with
IL-6. Survival curves of breast cancer patients with high IL-6 expression have reduction
in survival compared to patients with low IL-6 expression level Log-rank test (p<0.0001).
C, Survival curves of breast cancer patients with high co-expression of OSM and IL-6
also demonstrate a reduction in survival compared to patients with low co-expression of
both OSM and IL-6 Log-rank test (p=0.0091). D, Two-way correlation analysis depicts a
statistically significant correlation between OSM and IL-6 expression levels in breast
cancer patients with a Spearman coefficient of 0.576. (p<0.0001).
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Figure 4.2.

OSM breast cancer patient serum levels correlate with IL-6 levels

Figure 4. 2. OSM breast cancer patient serum levels correlate with IL-6 levels.
Sera from breast cancer patients were procured from various sources, and OSM
levels (A) and IL-6 levels (B) were measured by ELISA. When OSM and IL-6 were
assessed between normal patients versus patients with non-metastatic or metastatic breast
cancer, there was a significant increase in serum OSM and IL-6 levels in both patients
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with non-metastatic or metastatic breast cancer versus normal patients. C, Patient sera
with undetectable OSM levels also have low IL-6 levels (8.5 pg/ml), while patient sera
with detectable levels of OSM have high levels of IL-6 (89 pg/ml). D, The serum
cytokines concentration data was then assessed for correlation and suggests that higher
levels of serum OSM correlates with higher levels of serum IL-6 (Spearman Correlation
coefficient = 0.923 (95% CI 0.825, 1.0) P<0.0001). Data expressed as mean +/- SEM.
and assessed by one-way ANOVA with Tukey’s post-test*p<0.05, **p<0.01,
***p<0.001.
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Figure 4.3.

OSM induces IL-6 in an animal model of human breast cancer
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Figure 4.3. OSM induces IL-6 in an animal model of human breast cancer.
A,.MDATO/OSM cells were injected orthotopically in vivo in athymic nude mice.
After the tumors became palpable, the animals were given tetracycline, and after one
week, the animals were sacrificed and tumors harvested. Western blot analysis of the
tumors indicates that OSM levels increase in response to tetracycline administration
(top). Densitometry of western blots indicate a 40-fold increase in tumor OSM in animals
given tetracycline compared to animals given control water (bottom). B, IL-6 levels in
the tumor, as assessed by western blot, also show similarly elevated levels in the
tetracycline-treated animals. C, Sera collected from the animals were assessed for hOSM
and hIL-6 levels by ELISA. Animals given tetracycline have an ~10-fold increase in
mean serum hOSM levels and an ~100-fold increase in mean serum hIL-6 levels. Data
expressed as mean +/- SEM, and significance assessed by two-tailed student’s t-test.
*p<0.05.
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Figure 4.4.

OSM induces IL-6 secretion in an ER-dependent manner
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Figure 4.4. OSM induces IL-6 secretion in an ER-dependent manner.
A, IL-6 secretion levels were measured by ELISA on CM collected from various
OSM-treated cells. ER- MDA-MB-231, MDA-MB-468, and 4T1.2 cells display high
(over 4-fold) levels of OSM-induced IL-6 secretion, while ER+ MCF7, and T47D cells
do not. B, OSM also induces IL-6 secretion in PC3 and DU145 (prostate) and HeLa
(ovarian) ER- non-breast cancer cell types. C, MDA-MB-231 cells were transfected with
an ERα expression vector, and the presence of ERα in transfected colonies was
determined by western blot. The two ER expressing cell lines are designated as
MDAER+/C7 and MDA ER+/H6. D, MDAER+/C7 cells secrete 9-fold less IL-6 and MDAER+/H6
cells secrete 12-fold less IL-6 in response to OSM compared to the parental MDA-MB231 cells. Data expressed as mean ± SEM and significance assessed by one-way ANOVA
with Tukey’s post-test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 4.5.

OSM signals through STAT3 in ER- MDA-MB-231 cells to induce IL6
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Figure 4.5. OSM signals through STAT3 in ER- MDA-MB-231 cells to induce IL-6.
A, OSM induces the phosphorylation of multiple signaling pathways including
ERK, JNK, AKT, and STAT3 as assessed by western blot. Overall, phosphorylation of
STAT3 and ERK occurs faster than other signaling pathway proteins. B, With STAT3
suppression by STAT3 siRNA, there is little induction of Y705 phosphorylation of
STAT3 by OSM. Additionally, OSM-induced IL-6, as detected by western blot, is also
suppressed. C, STAT3 siRNA suppressed OSM induction of IL-6 production as assessed
by ELISA in MDA-MB-231 cells. Data expressed as mean ± SEM, and significance
assessed by one-way ANOVA with Tukey’s post-test. *p<0.05.
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Figure 4.6. OSM and IL-1β expression is higher in invasive breast cancer
compared to normal tissue and correlates with higher lymph node metastasis,
decreased survival, and IL-6 levels
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Figure 4.6. OSM and IL-1β expression is higher in invasive breast cancer compared to
normal tissue and correlates with higher lymph node metastasis, decreased survival, and
IL-6 levels.
A, Using the FINAK dataset obtained from Oncomine™ we assessed stromal
tissue expression of OSM and IL-1β. Stromal tissue expression of OSM is 5.9-fold higher
in invasive breast cancer patients compared to normal patients. B, Similarly, expression
of IL-1β is 5.4-fold higher in the stromal tissue of invasive breast cancer patients
compared to normal patients. C, Using the Curtis dataset obtained from Oncomine™, we
correlated OSM and IL-1β tissue expression levels to the number of lymph node
metastases. Patients with high OSM (Left), high IL-1β (Center), and high co-expression
of both OSM and IL-1β (Right) have significantly higher number of lymph node
metastatic nodules compared to the respective low expression group. D, High coexpression of both OSM and IL-1β leads to a decreased overall patient survival. Log-rank
test (p=0.0401). E, Expression of OSM, IL-1β, and IL-6 were analyzed in a three-way
correlation analysis with OSM on the x-axis, IL-6 on the y-axis, and IL-1β on the z-axis.
There is significant correlation with a coefficient of 0.6001, with a p-value of 2.2 x 10-23.
Bar and scatter plot data expressed as mean ± SEM, and significance assessed by twotailed student’s t-test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 4.7.

OSM and IL-1β activate separate signaling pathways and
synergistically induce IL-6 secretion
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Figure 4.7. OSM and IL-1β activate separate signaling pathways and synergistically
induce IL-6 secretion.
A, IL-1β alone promotes IL-6 production in MDA-MB-231 and MCF7 cells,
while a combination of OSM and IL-1β causes a synergistic response in IL-6 secretion.
T47D cells do not produce IL-6 in any of these conditions. B, Reduced IL-6 scale to
allow visualization of MCF7 cell-IL-6 induction. C, With a 20-minute cytokine treatment
with OSM, phosphorylation of STAT3 but not p65 is upregulated, while ERK is
moderately phosphorylated. MCF7 cells have a weak STAT3 induction in response to
OSM. A 20-minute cytokine treatment with IL-1β on the other hand induces the
phosphorylation of p65 but not STAT3. D, The above phosphorylation of STAT3 and
p65 are sustained at 72 hours with the same cytokine treatments. E, MCF7 cells were
treated with OSM and/or IL-1β for 48 hours, and the cell lysates were run through an
immunoprecipitation with an ER pulldown. The eluate was then immunoblotted with the
input for STAT3. Lysates collected from MCF7 cells treated with OSM or with both
cytokines have significantly reduced ER-STAT3 interaction. Data expressed as mean ±
SEM, and significance assessed by one-way ANOVA with Tukey’s post-test. *p<0.05,
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Figure 4.8.

OSM and IL-1β promote IL-6 expression in a breast cancer cellsubtype specific manner

Figure 4.8. OSM and IL-1β promote IL-6 expression in a breast cancer cell-subtype
specific manner.
OSM signals through the STAT3 pathway and leads to IL-6 induction in MDAMB-231 cells, while IL-1β induces IL-6 through the p65 pathway. In MCF7 cells, ER
may be interacting with STAT3 to suppress IL-6 production. There may also be some
crosstalk-like interaction between STAT3 and p65, however the exact nature of this
interaction is not known (59, 74).
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Chapter Four: Supplemental Figures

Figure 4.S1.

OSM and IL-6 serum concentration is correlated in vivo

Figure 4.S1. OSM and IL-6 serum concentration is correlated in vivo.
OSM and IL-6 serum concentrations in the MDATO/OSM mouse model were
assessed by ELISA, and the resultant numbers were analyzed using a correlation analysis.
OSM and IL-6 levels correlate with a spearman correlation coefficient of 0.9058 and a pvalue of 0.0034.

190

Figure 4.S2. IL-6 does not promote OSM secretion
Figure 4.S2. IL-6 does not promote OSM secretion.
MDA, T47D, and MCF7 cells were treated with IL-6, and secreted OSM levels in
the conditioned media were assessed by ELISA. IL-6 did not promote OSM secretion in
any of the cell lines tested.
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Figure 4.S3.

IL-6 does not promote OSM secretion
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Figure 4.S3. Stromal and tumor tissue expression of both OSM and IL-1β are higher in
ER- patients.
A, Stromal OSM and B, IL-1β expression is significantly higher in patients with
ER- breast cancer compared to ER+ breast cancer, as assessed using the Finak
Oncomine™ dataset. Additionally, using the Curtis Oncomine™ dataset, tumor tissue
expression of OSM (C) and IL-1β (D) is also significantly higher in ER- breast cancer
patients compared to patients with ER+ breast cancer. Data expressed as log2 mediancentered ratio +/- SD and significance assessed by two-tailed student’s t-test. *p<0.05,
**p<0.01, ***p<0.001.
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Figure 4.S4.

IL-1β mRNA expression levels correlate with both OSM and IL-6 in
breast cancer patients

Figure 4.S4. IL-1β mRNA expression levels correlate with both OSM and IL-6 in breast
cancer patients.
The Curtis breast cancer dataset was assessed for OSM, IL-6, and IL-1β tumor
mRNA expression levels. A, OSM and IL-1β expression levels correlates with each other
with a spearman coefficient of 0.604 with a p value of less than 0.0001. B, IL-6 and IL1β expression levels correlates with each other with a spearman coefficient of 0.526 and a
p value of less than 0.0001. Correlation coefficients were assessed using the Spearman
correlation analysis.

194

Figure 4.S5.

OSM and IL-1β promotes EMT-like morphology in T47D cells

Figure 4.S5. OSM and IL-1β promotes EMT-like morphology in T47D cells.
T47D cells did not produce any IL-6 under any treatment conditions. To assess
whether the cytokines were having any effect on T47D cells, they were treated with 10
ng/mL of OSM and/or IL-1β for 72 hours and the cell morphology assessed by phase
contrast microscopy. Treatment of the cells with OSM and/or IL-1β promotes an EMTlike cell morphology with the cells becoming more mesenchymal and spreading apart
from each other. Red arrows indicate areas with invadopodium formation. These results
indicate that OSM and IL-1β have an effect on T47D cells but does not produce IL-6 in
response.
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Figure 4.S6.

ERK signaling is required for MCF7’s synergistic response to OSM
and IL-1β
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Figure 4.S6. ERK signaling is required for MCF7’s synergistic response to OSM and IL1β.
MCF7 and MDA-MB-231 cells were treated with 10 ng/mL of OSM and/or IL-1β
with or without an ERK inhibitor (50 µM, PD98059) or carrier (DMSO) for 48 hours. A,
The ERK inhibitor suppresses pERK levels in both MCF7 and MDA-MB-231 cells. B,
The ERK inhibitor suppresses IL-6 secretion in both IL-1β and OSM+ IL-1β treatment
groups in MCF7 cells, but not in C, MDA-MB-231 cells.
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Figure 4.S7.

STAT3 siRNA does not affect IL-1β-induced IL-6 secretion

Figure 4.S7. STAT3 siRNA does not affect IL-1β-induced IL-6 secretion.
MDA-MB-231 and MCF7 cells were treated with 25 nM of STAT3 siRNA with
or without 10 ng/mL of OSM and/or IL-1β for 72 hours. Although the usage of the
STAT3 siRNA suppresses OSM-induced IL-6 secretion, it had no effect on IL-1βinduced IL-6 secretion.
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Figure 4.S8.

CAPE inhibits OSM-induced IL-6 secretion

Figure 4.S8. CAPE inhibits OSM-induced IL-6 secretion.
MDA-MB-231 cells were treated with various concentrations of the p65 inhibitor
CAPE with or without 25 ng/mL of OSM. By ELISA, CAPE inhibits OSM-induced IL-6
secretion by approximately 6-fold with 20 µM of the inhibitor.
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